

Physiologic, subjective, and behavioral effects of amphetamine, phenmetrazine, and methylphenidate in man

Clinical Pharmacology and Therapeutics

12, 245-258

DOI: 10.1002/cpt1971122part1245

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effect of phenmetrazine, aminorex and (±)-chloramphetamine on the motor activity and turnover rate of brain catecholamines. British Journal of Pharmacology, 1971, 43, 570-579.	5.4	49
2	An Analysis of Amphetamine Toxicity and Patterns of Use. Journal of Psychedelic Drugs, 1972, 5, 113-130.	0.3	16
3	Chapter 2. Antidepressives and Stimulants. Annual Reports in Medicinal Chemistry, 1972, , 18-30.	0.9	0
4	Clinical Use of Psychotherapeutic Drugs2 II. Drugs, 1972, 4, 361-410.	10.9	19
5	A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. European Journal of Clinical Pharmacology, 1973, 6, 163-169.	1.9	94
6	Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. European Journal of Clinical Pharmacology, 1973, 6, 170-176.	1.9	91
7	Human Pharmacology of Drugs of Abuse with Emphasis on Neuroendocrine Effects. Progress in Brain Research, 1973, , 373-381.	1.4	7
8	General Pharmacology of Amphetamine-Like Drugs. , 1973, , 3-275.		1
9	Methylphenidate Therapy in Primary Alveolar Hypoventilation. Chest, 1973, 64, 137-140.	0.8	4
10	The Effects of Cocaine on Depressed Patients. American Journal of Psychiatry, 1974, 131, 511-517.	7.2	180
11	The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action. Psychopharmacology, 1975, 43, 163-168.	3.1	29
12	Self-administration of CNS stimulants by dog. Psychopharmacology, 1975, 43, 207-213.	3.1	33
13	Methylphenidate in Children: Effects upon Cardiorespiratory Function on Exertion. International Journal of Mental Health, 1975, 4, 119-131.	1.3	18
14	Intravenous self-administration of d- and l-amphetamine by dog. European Journal of Pharmacology, 1975, 32, 344-348.	3.5	18
15	Pharmacological approaches to treating the obese patient. Clinics in Endocrinology and Metabolism, 1976, 5, 455-479.	1.6	15
16	Role of noradrenergic and dopaminergic processes in amphetamine self-administration. Pharmacology Biochemistry and Behavior, 1976, 5, 477-482.	2.9	131
17	Cardiovascular Responses of Hyperactive Children to Methylphenidate. JAMA - Journal of the American Medical Association, 1976, 236, 2870.	7.4	58
18	Cardiovascular and Subjective Effects of Intravenous Cocaine Administration in Humans. Archives of General Psychiatry, 1976, 33, 983.	12.3	307

#	ARTICLE	IF	CITATIONS
19	Psychologic and Neuroendocrine Response to Methylphenidate. Archives of General Psychiatry, 1977, 34, 1103.	12.3	37
20	A pharmacologic comparison of 3,4-methylenedioxyamphetamine and LSD in the chronic spinal dog. European Journal of Pharmacology, 1977, 46, 339-349.	3.5	15
21	Aspects of the psychopathology and pathophysiology of addiction. Drug and Alcohol Dependence, 1977, 2, 185-202.	3.2	31
23	Drug-produced changes in human social behavior: Facilitation by d-amphetamine. Pharmacology Biochemistry and Behavior, 1977, 7, 365-372.	2.9	31
24	Dopaminergic agonist properties of ephedrine-theoretical implications. Psychopharmacology, 1977, 55, 115-120.	3.1	38
25	Actions of amphetamine and antagonists on pupil diameter in the chronic sympathectomized dog. Psychopharmacology, 1977, 53, 115-120.	3.1	13
26	Comparative effects of d-amphetamine, l-amphetamine and methylphenidate on mood in man. Psychopharmacology, 1977, 53, 1-12.	3.1	83
27	The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacology, 1977, 52, 251-255.	3.1	38
28	Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology, 1978, 58, 189-195.	3.1	71
29	Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. Psychopharmacology, 1978, 57, 83-87.	3.1	32
30	Methamphetamine and diphenhydramine effects on the rate of cognitive processing. Psychopharmacology, 1978, 59, 13-19.	3.1	29
31	Comparison of oral and intravenous methylphenidate. Psychopharmacology, 1978, 59, 75-78.	3.1	17
32	Effects of d-amphetamine on speaking in isolated humans. Pharmacology Biochemistry and Behavior, 1978, 9, 57-63.	2.9	29
33	Clinical Psychology in the Chemical Environment. Psychological Reports, 1978, 43, 247-276.	1.7	10
34	Secondary Mania. Archives of General Psychiatry, 1978, 35, 1333.	12.3	550
35	Studies on central functional equivalence, m: classification of several psychomotor stimulants and anorectic agents. Current Medical Research and Opinion, 1979, 6, 135-148.	1.9	3
36	Hemodynamic effects of oral ephedrine given alone or combined with nitroprusside infusion in patients with severe left ventricular failure. American Journal of Cardiology, 1979, 43, 79-85.	1.6	17
37	Human pharmacology of narcotic antagonists.. British Journal of Clinical Pharmacology, 1979, 7, 287S-290S.	2.4	46

#	ARTICLE	IF	CITATIONS
38	Addiction liability of fenfluramine. Current Medical Research and Opinion, 1979, 6, 118-124.	1.9	8
39	Abuse of Prescribed Stimulant Medication by a 13-Year-Old Hyperactive Boy. Journal of the American Academy of Child Psychiatry, 1979, 18, 170-175.	0.7	34
40	Aversive stimulus properties of drugs. Neuropharmacology, 1979, 18, 971-979.	4.1	139
41	Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: Regional differences. Brain Research, 1979, 162, 77-88.	2.2	22
42	Paradoxical tranquilizing and emotion-reducing effects of nicotine.. Psychological Bulletin, 1979, 86, 643-661.	6.1	209
43	Drug preference and mood in humans: d-amphetamine. Psychopharmacology, 1980, 71, 275-279.	3.1	180
44	Cocaine effects in sleep-deprived humans. Psychopharmacology, 1980, 72, 1-8.	3.1	66
45	Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants. Neuroscience and Biobehavioral Reviews, 1980, 4, 281-375.	6.1	106
46	Psychopharmacology of anorectic drugs in man. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1980, 4, 371-374.	0.6	1
47	Amphetamine-Induced Dysphoria in Postmenopausal Women. British Journal of Psychiatry, 1981, 138, 470-473.	2.8	22
48	Liking of the First Drug Experience: A Comparison of Ten Drugs in Opiate Addicts. Psychological Reports, 1981, 48, 647-668.	1.7	6
49	Effects of Dextroamphetamine Sulfate on Repeated Acquisition Behavior and Mood in Humans: A Preliminary Report. Psychological Record, 1981, 31, 29-41.	0.9	4
50	Drug preference and mood in humans: Repeated assessment of d-amphetamine. Pharmacology Biochemistry and Behavior, 1981, 14, 159-163.	2.9	74
51	Human social conversation: Effects of ethanol, secobarbital and chlorpromazine. Pharmacology Biochemistry and Behavior, 1981, 14, 353-360.	2.9	31
52	d-Pseudoephedrine. Folia Pharmacologica Japonica, 1982, 79, 401-408.	0.2	2
53	Psychopharmacology of hunger and food intake in humans. , 1982, 19, 417-434.		6
54	Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacology Biochemistry and Behavior, 1982, 17, 539-545.	2.9	20
55	A comparison of the subjective and cardiovascular effects of cocaine and procaine in humans. Pharmacology Biochemistry and Behavior, 1983, 18, 711-716.	2.9	60

#	ARTICLE	IF	CITATIONS
56	A comparison of the subjective and cardiovascular effects of cocaine and lidocaine in humans. Pharmacology Biochemistry and Behavior, 1983, 18, 123-127.	2.9	108
57	Effects of ethanol on cigarette smoking by volunteers without histories of alcoholism. Psychopharmacology, 1983, 82, 1-5.	3.1	83
58	Assessment of dependence potential of drugs in humans using multiple indices. Psychopharmacology, 1983, 81, 144-149.	3.1	51
59	Human progressive-ratio performance: Maintenance by pentobarbital. Psychopharmacology, 1983, 79, 4-9.	3.1	30
60	A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology, 1983, 80, 199-205.	3.1	78
61	Differential Effects of Diazepam and Pentobarbital on Mood and Behavior. Archives of General Psychiatry, 1983, 40, 865.	12.3	89
62	Diazepam and methadone interactions in methadone maintenance. Clinical Pharmacology and Therapeutics, 1984, 36, 534-541.	4.7	70
63	Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects. Psychopharmacology, 1984, 84, 147-154.	3.1	78
64	The effect of d-amphetamine and ephedrine on smoking attitude and behavior. Addictive Behaviors, 1984, 9, 335-345.	3.0	15
65	Possible involvement of amine oxidase inhibition in the sympathetic activation induced by khat (catha) Tj ETQq1 1 0.784314 rrgBT /Over	4.1	24
66	Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon. Psychopharmacology, 1985, 85, 476-482.	3.1	15
67	Information processing components of the auditory event related potential are reduced by cocaine. Psychopharmacology, 1985, 87, 178-185.	3.1	31
68	The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology, 1985, 86, 307-312.	3.1	98
69	A comparison of the acute effects of dextroamphetamine and fenfluramine in depression. Biological Psychiatry, 1985, 20, 1090-1097.	1.3	11
70	Methylphenidate infusion in euthymic bipolars: Effect of carbamazepine pretreatment. Psychiatry Research, 1985, 16, 303-308.	3.3	26
71	Chronic cocaine administration depletes tyrosine hydroxylase immunoreactivity in the rat brain nigral striatal system: Quantitative light microscopic studies. Experimental Neurology, 1986, 94, 744-756.	4.1	40
72	Clinical use of appetite suppressants. Drug and Alcohol Dependence, 1986, 17, 151-167.	3.2	13
73	Subjective effects of Khat chewing in humans. Drug and Alcohol Dependence, 1986, 18, 97-105.	3.2	46

#	ARTICLE	IF	CITATIONS
74	Affective Illness in Substance Abusers. <i>Psychiatric Clinics of North America</i> , 1986, 9, 503-514.	1.3	35
75	Dextroamphetamine-induced arousal in human subjects as a model for mania. <i>Psychological Medicine</i> , 1986, 16, 323-329.	4.5	139
76	The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. <i>Psychopharmacology</i> , 1986, 89, 301-6.	3.1	58
77	Acute marijuana effects on social conversation. <i>Psychopharmacology</i> , 1986, 89, 234-238.	3.1	28
78	The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d-amphetamine in humans. <i>Pharmacology Biochemistry and Behavior</i> , 1986, 24, 1665-1672.	2.9	98
79	An Outline of Hazardous Side Effects of Ritalin (Methylphenidate). <i>Substance Use and Misuse</i> , 1986, 21, 837-841.	0.6	4
80	Myocardial Infarction With Topical Cocaine Anesthesia for Nasal Surgery. <i>JAMA Otolaryngology</i> , 1986, 112, 988-990.	1.2	86
81	Psychophysiological Effects of Methylphenidate (Ritalin). <i>Psychological Reports</i> , 1987, 61, 315-336.	1.7	15
82	Individual Differences in Behavioral and Subjective Responses to Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 1987, 11, 52-59.	2.4	123
83	Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. <i>Biological Psychiatry</i> , 1987, 22, 1357-1368.	1.3	169
84	Ephedrine Psychosis Rediscovered. <i>British Journal of Psychiatry</i> , 1987, 150, 258-261.	2.8	59
85	Provocative tests with psychostimulant drugs in schizophrenia. <i>Psychopharmacology</i> , 1987, 91, 415-433.	3.1	458
86	An examination of the intravenous self-administration of phenylpropanolamine using a cocaine substitution procedure in the baboon. <i>Pharmacology Biochemistry and Behavior</i> , 1987, 28, 389-392.	2.9	2
87	Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. <i>Annals of Neurology</i> , 1988, 23, 94-97.	5.3	353
88	Clinical toxicity of cocaine adulterants. <i>Annals of Emergency Medicine</i> , 1988, 17, 1243-1247.	0.6	84
89	Effects of alcohol on speaking in isolated humans. <i>Psychopharmacology</i> , 1988, 95, 189-94.	3.1	27
90	Discriminative stimulus and subjective effects of smoked marijuana in humans. <i>Psychopharmacology</i> , 1988, 94, 206-12.	3.1	71
91	Phenylpropanolamine: reinforcing and subjective effects in normal human volunteers. <i>Psychopharmacology</i> , 1988, 96, 212-7.	3.1	23

#	ARTICLE	IF	CITATIONS
92	Discriminative stimulus effects of caffeine and benzphetamine in amphetamine-trained volunteers. Psychopharmacology, 1988, 96, 302-308.	3.1	75
93	Urinary phenylacetate and response to methylphenidate. Journal of Psychiatric Research, 1988, 22, 131-139.	3.1	11
94	Organic Causes of Mania. Mayo Clinic Proceedings, 1988, 63, 906-912.	3.0	53
95	Psychophysiological Effects of Oral Ethanol in Alcoholics and Social Drinkers. Alcoholism: Clinical and Experimental Research, 1988, 12, 30-38.	2.4	47
96	Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 724-731.	1.9	84
97	Effects of food deprivation on subjective responses to d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 1989, 34, 791-795.	2.9	21
98	Monologue speech: Effects of d-amphetamine, secobarbital and diazepam. Pharmacology Biochemistry and Behavior, 1989, 34, 609-618.	2.9	19
99	Effects of methylphenidate on cardiovascular responses in attention deficit hyperactivity disorder adolescents. Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine, 1989, 10, 179-183.	0.3	34
100	Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology, 1989, 98, 81-88.	3.1	95
101	Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Research, 1989, 505, 7-11.	2.2	86
102	Mechanism of dexamphetamine-induced mydriasis in the anaesthetized rat. British Journal of Pharmacology, 1989, 96, 39-44.	5.4	6
103	Morphine-Induced Metabolic Changes in Human Brain. Archives of General Psychiatry, 1990, 47, 73.	12.3	122
104	Effects of a 24-hour fast on cigarette smoking in humans. Addiction, 1990, 85, 555-560.	3.3	19
105	Stimulant drug treatment of hyperactivity: Biochemical correlates. Clinical Pharmacology and Therapeutics, 1990, 48, 57-66.	4.7	76
106	Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology Biochemistry and Behavior, 1990, 37, 511-522.	2.9	35
107	Conditioned aversion after delay place conditioning with amphetamine. Pharmacology Biochemistry and Behavior, 1990, 35, 89-92.	2.9	41
108	Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology, 1990, 102, 183-190.	3.1	66
109	Amphetamine-like effects in humans of the khat alkaloid cathinone.. British Journal of Clinical Pharmacology, 1990, 30, 825-828.	2.4	211

#	ARTICLE	IF	CITATIONS
110	Clinical effects of methamphetamine vapor inhalation. Life Sciences, 1991, 49, 953-959.	4.3	39
111	Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug and Alcohol Dependence, 1991, 28, 3-48.	3.2	138
112	Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug and Alcohol Dependence, 1991, 28, 83-111.	3.2	181
113	Amphetamine actions on pre- and postpubertal rat hippocampal dentate granule neurons. Brain Research, 1991, 556, 33-43.	2.2	4
114	The pharmacology of psychoactive alkaloids from Ephedra and Catha. Journal of Ethnopharmacology, 1991, 32, 201-208.	4.1	103
115	Evaluation of the abuse potential of the novel analgesic flupirtine maleate. Drug and Alcohol Dependence, 1991, 27, 101-113.	3.2	7
116	Diazepam Preference in Males with and without an Alcoholic First-Degree Relative. Alcoholism: Clinical and Experimental Research, 1991, 15, 593-600.	2.4	18
117	Drug discrimination methods in human drug abuse liability evaluation. Addiction, 1991, 86, 1587-1594.	3.3	28
118	Performance and physiological measures in abuse liability evaluation. Addiction, 1991, 86, 1595-1600.	3.3	18
119	Human drug abuse liability assessment: opioids and analgesics. Addiction, 1991, 86, 1615-1628.	3.3	32
120	Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans. Addiction, 1991, 86, 1633-1640.	3.3	42
121	Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology, 1991, 103, 436-442.	3.1	81
122	Effects of Food Deprivation on Subjective Effects and Self-Administration of Marijuana in Humans. Psychological Reports, 1991, 68, 1263-1274.	1.7	16
123	The Efficacy of Ergogenic Agents in Athletic Competition: Part II: Other Performance-Enhancing Agents. Annals of Pharmacotherapy, 1992, 26, 653-659.	1.9	40
124	Simulated Sustained Flight Operations and Performance, Part 2: Effects of Dextro-Methamphetamine. Military Psychology, 1992, 4, 267-287.	1.1	12
125	Triazolam as a discriminative stimulus in humans. Drug and Alcohol Dependence, 1992, 30, 133-142.	3.2	19
126	Effects of setting on the subjective and behavioral effects of d-amphetamine in humans. Addictive Behaviors, 1992, 17, 27-33.	3.0	30
127	Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug and Alcohol Dependence, 1992, 30, 263-274.	3.2	50

#	ARTICLE	IF	CITATIONS
128	Effects of fasting on responses to intravenous fentanyl in healthy volunteers. Journal of Substance Abuse, 1992, 4, 197-207.	1.1	11
129	Verapamil and Valproic Acid Treatment of Prolonged Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 271-275.	0.5	42
130	The Importance of Drug Self-Administration Studies in the Analysis of Abuse Liability. American Journal on Addictions, 1992, 1, 139-149.	1.4	1
131	Stimulus functions of caffeine in humans: Relation to dependence potential. Neuroscience and Biobehavioral Reviews, 1992, 16, 273-287.	6.1	41
132	Self-administration of pentobarbital in light and moderate alcohol drinkers. Pharmacology Biochemistry and Behavior, 1992, 43, 563-569.	2.9	6
133	Effects of the putative dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 on the discriminative stimulus properties of cocaine. Psychopharmacology, 1992, 107, 73-77.	3.1	22
134	Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology, 1992, 107, 319-326.	3.1	57
135	Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology, 1992, 107, 352-358.	3.1	112
136	Subjective and psychomotor effects of bolus doses of nitrous oxide in humans. Human Psychopharmacology, 1993, 8, 97-106.	1.5	4
137	Reinforcing effects of extended inhalation of a low nitrous oxide concentration in humans. Pharmacology Biochemistry and Behavior, 1993, 46, 927-932.	2.9	16
138	Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology, 1993, 112, 324-330.	3.1	66
139	Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. Psychopharmacology, 1993, 111, 306-314.	3.1	33
140	Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep. American Journal of Obstetrics and Gynecology, 1993, 169, 888-897.	1.3	30
141	Reinforcing effects of extended inhalation of nitrous oxide in humans. Drug and Alcohol Dependence, 1993, 31, 265-280.	3.2	43
142	Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug and Alcohol Dependence, 1993, 32, 93-106.	3.2	66
143	Variability in subjective responses to cocaine: Initial experiences of college students. Addictive Behaviors, 1993, 18, 445-453.	3.0	67
144	Discriminative stimulus effects of buspirone in humans.. Experimental and Clinical Psychopharmacology, 1993, 1, 173-187.	1.8	11
145	What's the stimulus?. Behavioral and Brain Sciences, 1993, 16, 664-664.	0.7	0

#	ARTICLE	IF	CITATIONS
146	Animal models: Nature made us, but was the mold broken?. Behavioral and Brain Sciences, 1993, 16, 664-680.	0.7	2
147	Species and individual differences in communication based on private states. Behavioral and Brain Sciences, 1993, 16, 627-642.	0.7	76
148	Perhaps Sisyphus is the relevant model for animal-language researchers. Behavioral and Brain Sciences, 1993, 16, 642-643.	0.7	0
149	Communication and internal states: What is their relationship?. Behavioral and Brain Sciences, 1993, 16, 643-644.	0.7	2
150	The status of private events in behavior analysis. Behavioral and Brain Sciences, 1993, 16, 644-644.	0.7	4
151	The outside route to the inside story. Behavioral and Brain Sciences, 1993, 16, 644-645.	0.7	2
152	Animal communication of private states does not illuminate the human case. Behavioral and Brain Sciences, 1993, 16, 645-646.	0.7	3
153	Plausible reconstruction? No!. Behavioral and Brain Sciences, 1993, 16, 646-647.	0.7	0
154	No report; no feeling. Behavioral and Brain Sciences, 1993, 16, 647-648.	0.7	0
155	A human model for animal behavior. Behavioral and Brain Sciences, 1993, 16, 648-649.	0.7	1
156	Communication versus discrimination. Behavioral and Brain Sciences, 1993, 16, 649-650.	0.7	1
157	A promissory note is paid, but has this bought into an illusion?. Behavioral and Brain Sciences, 1993, 16, 650-651.	0.7	0
158	Difference without discontinuity. Behavioral and Brain Sciences, 1993, 16, 651-651.	0.7	0
159	Behaviorism is alive and well. Behavioral and Brain Sciences, 1993, 16, 651-652.	0.7	0
160	Pigeons and the problem of other minds. Behavioral and Brain Sciences, 1993, 16, 652-653.	0.7	2
161	Animal modeling in psychopharmacological contexts. Behavioral and Brain Sciences, 1993, 16, 653-654.	0.7	1
162	We can reliably report psychological states because they are neither internal nor private. Behavioral and Brain Sciences, 1993, 16, 654-654.	0.7	0
163	What's biological about the continuity?. Behavioral and Brain Sciences, 1993, 16, 654-655.	0.7	1

#	ARTICLE	IF	CITATIONS
164	Pigeons as communicators and thinkers:<i>Mon oncle d'Amerique deux?</i>. Behavioral and Brain Sciences, 1993, 16, 655-656.	0.7	0
165	The role of convention in the communication of private events. Behavioral and Brain Sciences, 1993, 16, 656-657.	0.7	23
166	Behaviorism, introspection and the mind's I. Behavioral and Brain Sciences, 1993, 16, 657-658.	0.7	0
167	Private states and animal communication. Behavioral and Brain Sciences, 1993, 16, 658-659.	0.7	0
168	Communicative acts and drug-induced feelings. Behavioral and Brain Sciences, 1993, 16, 659-660.	0.7	0
169	Animal models of human communication. Behavioral and Brain Sciences, 1993, 16, 660-660.	0.7	1
170	How do we know when private events control behavior?. Behavioral and Brain Sciences, 1993, 16, 660-661.	0.7	2
171	Cross-fertilization between research on interpersonal communication and drug discrimination. Behavioral and Brain Sciences, 1993, 16, 661-662.	0.7	2
172	Are some mental states public events?. Behavioral and Brain Sciences, 1993, 16, 662-663.	0.7	1
173	The assessment of intentionality in animals. Behavioral and Brain Sciences, 1993, 16, 663-663.	0.7	0
174	Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. European Psychiatry, 1993, 8, 201-208.	0.2	67
175	Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers. Neuropsychopharmacology, 1994, 10, 157-170.	5.4	25
176	Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology, 1994, 113, 381-387.	3.1	49
177	Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. Psychopharmacology, 1994, 115, 529-538.	3.1	54
178	The subjective, behavioral and cognitive effects of subanesthetic concentrations of isoflurane and nitrous oxide in healthy volunteers. Psychopharmacology, 1994, 114, 409-416.	3.1	47
179	Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. Psychopharmacology, 1994, 114, 417-423.	3.1	33
180	Methodological issues in the administration of multiple doses of smoked cocaine-base in humans. Pharmacology Biochemistry and Behavior, 1994, 47, 531-540.	2.9	34
181	Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 1994, 55, 569-580.	4.7	670

#	ARTICLE	IF	CITATIONS
182	Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). Drug and Alcohol Dependence, 1994, 35, 203-209.	3.2	45
183	Effects of marijuana history on the subjective, psychomotor, and reinforcing effects of nitrous oxide in humans. Drug and Alcohol Dependence, 1994, 36, 227-236.	3.2	14
184	The Effects of Cocaine in Buprenorphine-Maintained Outpatient Volunteers. American Journal on Addictions, 1994, 3, 129-143.	1.4	3
185	Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences, 1994, 54, 1215-1228.	4.3	81
186	Acute Effects of Tramadol in Methadone-Maintained Volunteers. Drugs, 1994, 47, 39-43.	10.9	42
187	HUMAN d-AMPHETAMINE DRUG DISCRIMINATION: METHAMPHETAMINE AND HYDROMORPHONE. Journal of the Experimental Analysis of Behavior, 1994, 61, 169-180.	1.1	54
188	Interaction of buprenorphine with cocaine-morphine combinations.. Experimental and Clinical Psychopharmacology, 1995, 3, 261-269.	1.8	13
189	Alprazolam and DN-2327 (Pazinaclone) in humans: Psychomotor, memory, subjective, and reinforcing effects.. Experimental and Clinical Psychopharmacology, 1995, 3, 39-48.	1.8	19
190	Role of dopamine in d-amphetamine-induced euphoria in normal, healthy volunteers.. Experimental and Clinical Psychopharmacology, 1995, 3, 371-381.	1.8	25
191	Buprenorphine treatment of opioid dependence: A review.. Experimental and Clinical Psychopharmacology, 1995, 3, 477-489.	1.8	125
192	Acute mood improvement after dextroamphetamine and methylphenidate in narcolepsy. Journal of Sleep Research, 1995, 4, 252-255.	3.2	12
193	Alprazolam absorption kinetics affects abuse liability*. Clinical Pharmacology and Therapeutics, 1995, 57, 356-365.	4.7	60
194	Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Human Psychopharmacology, 1995, 10, 111-125.	1.5	10
195	Effect of setting on the reinforcing and subjective effects of ethanol in social drinkers. Psychopharmacology, 1995, 118, 19-27.	3.1	119
196	Sudden Death in Individuals in Hobble Restraints During Paramedic Transport. Annals of Emergency Medicine, 1995, 25, 710-712.	0.6	104
197	Effects of subanesthetic concentrations of nitrous oxide on cold-pressor pain in humans. Pharmacology Biochemistry and Behavior, 1995, 51, 323-329.	2.9	22
198	Toxicity and Abuse of Prescribed Stimulants. International Journal of Psychiatry in Medicine, 1995, 25, 69-79.	1.8	3
199	Amphetamine on Rorschach Measures in Normal Subjects. Journal of Personality Assessment, 1995, 64, 456-465.	2.1	33

#	ARTICLE	IF	CITATIONS
200	Ritalintm for nicotine withdrawal: Nesbitt's paradox revisited. Addictive Behaviors, 1995, 20, 481-490.	3.0	13
201	Fetal responses to maternal and fetal methamphetamine administration in sheep. American Journal of Obstetrics and Gynecology, 1995, 173, 1592-1598.	1.3	46
202	Abuse Potential of Nicotine Replacement Therapies. CNS Drugs, 1995, 4, 456-468.	5.9	16
203	Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.. British Journal of Clinical Pharmacology, 1995, 39, 31-38.	2.4	41
204	Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug and Alcohol Dependence, 1995, 39, 55-62.	3.2	38
205	Effect of cocaine on vagal tone: a common factors approach. Drug and Alcohol Dependence, 1995, 37, 211-216.	3.2	19
206	Acute subjective responses to paroxetine in normal volunteers. Drug and Alcohol Dependence, 1995, 39, 223-230.	3.2	12
207	USE OF STIMULANTS IN THE MEDICALLY ILL. Psychiatric Clinics of North America, 1996, 19, 515-547.	1.3	110
208	Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biological Psychiatry, 1996, 39, 26-32.	1.3	102
209	Chronopharmacokinetics and Chronopharmacodynamics of Dextromethamphetamine in Man. Journal of Clinical Pharmacology, 1996, 36, 1051-1063.	2.0	42
210	The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Drug and Alcohol Dependence, 1996, 42, 133-142.	3.2	42
211	Acute stimulant response prediction of chronic trazodone effects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 815-824.	4.8	0
212	Pseudoephedrine is without ergogenic effects during prolonged exercise. Journal of Applied Physiology, 1996, 81, 2611-2617.	2.5	69
213	Effects of Befloxatone, a Reversible Selective Monoamine Oxidaseâ€A Inhibitor, on Psychomotor Function and Memory in Healthy Subjects. Journal of Clinical Pharmacology, 1996, 36, 942-950.	2.0	17
214	Comparison of Methods for the Assessment of Central Nervous System Stimulant Response after Dextroamphetamine Administration to Healthy Male Volunteers. Journal of Clinical Pharmacology, 1996, 36, 1039-1050.	2.0	20
215	The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. Clinical Autonomic Research, 1996, 6, 343-349.	2.5	7
216	Lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of nitrous oxide in healthy volunteers. Pharmacology Biochemistry and Behavior, 1996, 54, 501-508.	2.9	9
217	Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy Volunteers. Neuropsychopharmacology, 1996, 14, 233-241.	5.4	49

#	ARTICLE	IF	CITATIONS
218	Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. <i>Psychopharmacology</i> , 1996, 125, 346-354.	3.1	202
219	Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. <i>Psychopharmacology</i> , 1996, 125, 371-378.	3.1	85
220	Enhancement of cocaine's abuse liability in methadone maintenance patients. <i>Psychopharmacology</i> , 1996, 123, 15-25.	3.1	54
221	The discriminative stimulus effects of tripeleminamine in humans. <i>Psychopharmacology</i> , 1996, 126, 140-146.	3.1	2
222	Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. <i>Psychopharmacology</i> , 1996, 126, 286-292.	3.1	152
223	A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. <i>Psychopharmacology</i> , 1996, 125, 1-12.	3.1	26
224	Lack of Amphetamine-Like Effects After Administration of Mefenorex in Normal Young Subjects. <i>Human Psychopharmacology</i> , 1996, 11, 321-335.	1.5	6
225	Performance-Enhancing Drugs, Fair Competition, and Olympic Sport. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 231.	7.4	59
226	The Influence of Three L-Type Calcium Channel Blockers on Morphine Effects in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 1997, 85, 633-638.	2.2	14
227	Limbic-cortical dysregulation: a proposed model of depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1997, 9, 471-481.	1.8	1,350
228	Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 228-234.	1.9	95
229	The Influence of Three L-Type Calcium Channel Blockers on Morphine Effects in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 1997, 85, 633-638.	2.2	21
230	Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. <i>Experimental and Clinical Psychopharmacology</i> , 1997, 5, 28-38.	1.8	18
231	Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment. <i>Drug and Alcohol Dependence</i> , 1997, 47, 109-116.	3.2	29
232	Effects of information on the reinforcing, subjective, and psychomotor effects of nitrous oxide in healthy volunteers. <i>Drug and Alcohol Dependence</i> , 1997, 48, 85-95.	3.2	5
233	The effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers. <i>Drug and Alcohol Dependence</i> , 1997, 45, 63-70.	3.2	21
234	Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 1997, 45, 81-91.	3.2	41
235	Sensitivity and specificity to amphetamine of a french version of the 49-item form of the addiction research center inventory. <i>Drug and Alcohol Dependence</i> , 1997, 45, 177-183.	3.2	9

#	ARTICLE	IF	CITATIONS
236	High Dose Pimozide Does Not Block Amphetamine-Induced Euphoria in Normal Volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 56, 265-272.	2.9	159
237	Effects of d-Amphetamine in Grouped Versus Isolated Humans. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 57, 333-340.	2.9	26
238	Secobarbital in Humans Discriminating Triazolam Under Two-Response and Novel-Response Procedures. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 58, 983-991.	2.9	8
239	Safety of Cotinine in Humans: Physiologic, Subjective, and Cognitive Effects. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 57, 643-650.	2.9	65
240	Nicotine nasal spray and vapor inhaler: abuse liability assessment. <i>Psychopharmacology</i> , 1997, 130, 352-361.	3.1	72
241	Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. <i>Psychopharmacology</i> , 1997, 131, 9-18.	3.1	25
242	Pretreatment with Isradipine, a Calcium-Channel Blocker, Does Not Attenuate the Acute Behavioral Effects of Ethanol in Humans. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 539-547.	2.4	20
243	Individual Differences in the Biphasic Effects of Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1903-1911.	2.4	120
244	Stimulant Use in Sports. <i>American Journal on Addictions</i> , 1998, 7, 243-255.	1.4	5
245	The Abuse Potential of Zolpidem Administered Alone and With Alcohol. <i>Pharmacology Biochemistry and Behavior</i> , 1998, 60, 193-202.	2.9	18
246	Reinforcing Effects of Caffeine, Ephedrine, and Their Binary Combination in Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1998, 60, 685-693.	2.9	23
247	Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. <i>Human Psychopharmacology</i> , 1998, 13, 493-500.	1.5	10
248	Effects of (-)-ephedrine on locomotion, feeding, and nucleus accumbens dopamine in rats. <i>Psychopharmacology</i> , 1998, 135, 133-140.	3.1	28
249	Effects of dynorphin A(1-13) on opiate withdrawal in humans. <i>Psychopharmacology</i> , 1998, 137, 326-332.	3.1	34
250	Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. <i>Psychopharmacology</i> , 1998, 140, 191-201.	3.1	65
251	Abuse liability of flunitrazepam among methadone-maintained patients. <i>Psychopharmacology</i> , 1998, 140, 486-495.	3.1	39
252	A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users. <i>Drug and Alcohol Dependence</i> , 1998, 50, 129-136.	3.2	15
253	Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. <i>Drug and Alcohol Dependence</i> , 1998, 53, 17-30.	3.2	29

#	ARTICLE	IF	CITATIONS
254	Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug and Alcohol Dependence, 1998, 53, 49-66.	3.2	31
255	Over-the-Counter Stimulants: Abuse and Addiction. Mayo Clinic Proceedings, 1998, 73, 977-982.	3.0	24
256	Evaluation of Potential Pharmacotherapies. , 1998, , 209-238.		15
257	Parkinsonian patients report blunted subjective effects of methylphenidate.. Experimental and Clinical Psychopharmacology, 1998, 6, 54-63.	1.8	24
258	Discriminative and participant-rated effects of methylphenidate in children diagnosed with attention deficit hyperactivity disorder (ADHD).. Experimental and Clinical Psychopharmacology, 1998, 6, 375-389.	1.8	18
259	COMPARING SINGLE AND CUMULATIVE DOSING PROCEDURES IN HUMAN TRIAZOLAM DISCRIMINATORS. Journal of the Experimental Analysis of Behavior, 1999, 71, 417-437.	1.1	5
260	DELAY OR PROBABILITY DISCOUNTING IN A MODEL OF IMPULSIVE BEHAVIOR: EFFECT OF ALCOHOL. Journal of the Experimental Analysis of Behavior, 1999, 71, 121-143.	1.1	673
261	Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects. Fundamental and Clinical Pharmacology, 1999, 13, 582-594.	1.9	18
262	Ethanol Impairs Saccadic and Smooth Pursuit Eye Movements Without Producing Self-Reports of Sedation. Alcoholism: Clinical and Experimental Research, 1999, 23, 664-672.	2.4	45
263	A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence*. Clinical Pharmacology and Therapeutics, 1999, 66, 306-314.	4.7	28
264	Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology, 1999, 142, 132-138.	3.1	40
265	Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology, 1999, 144, 220-233.	3.1	86
266	Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology, 1999, 145, 39-51.	3.1	83
267	Acute effects of d -amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology, 1999, 145, 67-75.	3.1	180
268	Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology, 1999, 146, 33-41.	3.1	51
269	The Novel-Response Procedure in Humans. Pharmacology Biochemistry and Behavior, 1999, 64, 245-250.	2.9	15
270	Effects of Training Dose on the Relationship Between Discriminative-Stimulus and Self-Reported Drug Effects of d-Amphetamine in Humans. Pharmacology Biochemistry and Behavior, 1999, 64, 319-326.	2.9	21
271	Selegiline-induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal. Movement Disorders, 1999, 14, 246-251.	3.9	54

#	ARTICLE	IF	CITATIONS
272	Effects of naloxone on nitrous oxide actions in healthy volunteers. <i>Pain</i> , 1999, 83, 411-418.	4.2	22
273	Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. <i>Drug and Alcohol Dependence</i> , 1999, 55, 1-12.	3.2	63
274	Response patterns of the Spanish version of the 49-item short form of the Addiction Research Center Inventory after the use of sedatives, stimulants, and opioids. <i>Drug and Alcohol Dependence</i> , 1999, 55, 117-125.	3.2	11
275	Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. <i>Drug and Alcohol Dependence</i> , 1999, 56, 191-203.	3.2	41
276	Acute effect of ephedrine on 24-h energy balance. <i>Clinical Science</i> , 1999, 96, 483-491.	4.3	31
277	Methylphenidate: Increased Abuse or Appropriate Use ?. <i>Journal of the American Pharmacists Association</i> , 1999, 39, 526-530.	0.5	30
278	Psychotropic Drugs Used in Anesthesia Practice. <i>Anesthesiology</i> , 1999, 90, 269-288.	2.5	36
279	Behavioral and Physiological Effects of Remifentanyl and Alfentanil in Healthy Volunteers. <i>Anesthesiology</i> , 1999, 90, 718-726.	2.5	51
280	Acute Effects of Estradiol Pretreatment on the Response to <i>d</i> -Amphetamine in Women. <i>Neuroendocrinology</i> , 2000, 71, 51-59.	2.5	89
281	Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy. <i>Clinical Neuropharmacology</i> , 2000, 23, 149-156.	0.7	283
282	Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 643-657.	2.1	16
283	Clinical pharmacology of psychotropic drugs. <i>Human Psychopharmacology</i> , 2000, 15, 361-387.	1.5	14
284	Neurological complications of drug abuse: pathophysiological mechanisms. <i>European Journal of Neurology</i> , 2000, 7, 595-606.	3.3	160
285	Subjective and Objective Responses to Ethanol in Moderate/Heavy and Light Social Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 789-794.	2.4	155
286	Drugs and nutrition. <i>Journal of Science and Medicine in Sport</i> , 2000, 3, 339-359.	1.3	0
287	Effects of Isradipine, a Dihydropyridine-Class Calcium Channel Antagonist, on D-Methamphetamine-Induced Cognitive and Physiological Changes in Humans. <i>Neuropsychopharmacology</i> , 2000, 22, 504-512.	5.4	71
288	Acute Effects of <i>d</i> -Amphetamine During the Early and Late Follicular Phases of the Menstrual Cycle in Women. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 66, 509-515.	2.9	80
289	Mecamylamine Blockade of Both Positive and Negative Effects of IV Nicotine in Human Volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 66, 637-643.	2.9	33

#	ARTICLE	IF	CITATIONS
290	Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. <i>Psychopharmacology</i> , 2000, 152, 31-39.	3.1	119
291	Impact of family history of alcoholism on cocaine-induced subjective effects and pharmacokinetic profile. <i>Psychopharmacology</i> , 2000, 152, 268-274.	3.1	8
292	Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine. <i>Psychopharmacology</i> , 2000, 153, 103-110.	3.1	13
293	Abuse liability assessment of sibutramine, a novel weight control agent. <i>Psychopharmacology</i> , 2000, 147, 339-346.	3.1	41
294	Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer. <i>Psychopharmacology</i> , 2000, 148, 272-280.	3.1	25
295	An evaluation of the abuse potential of modafinil using methylphenidate as a reference. <i>Journal of Psychopharmacology</i> , 2000, 14, 53-60.	4.0	221
296	Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine/naloxone tablet. <i>Drug and Alcohol Dependence</i> , 2000, 58, 143-152.	3.2	116
297	Naltrexone does not block the subjective effects of oral Δ^9 -tetrahydrocannabinol in humans. <i>Drug and Alcohol Dependence</i> , 2000, 59, 251-260.	3.2	58
298	Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. <i>Drug and Alcohol Dependence</i> , 2000, 59, 261-275.	3.2	120
299	Psychiatric Complications of Ma-Huang. <i>Psychosomatics</i> , 2000, 41, 58-62.	2.5	43
300	Brain Mapping: The Applications. , 2000, , 491-522.		7
301	Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo. <i>Drug and Alcohol Dependence</i> , 2001, 61, 249-260.	3.2	6
302	Psychometric assessment of the Hallucinogen Rating Scale†. <i>Drug and Alcohol Dependence</i> , 2001, 62, 215-223.	3.2	67
303	Morphine responses in humans: a retrospective analysis of sex differences. <i>Drug and Alcohol Dependence</i> , 2001, 63, 23-28.	3.2	50
304	Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. <i>Drug and Alcohol Dependence</i> , 2001, 63, 155-167.	3.2	32
305	Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity. <i>Drug and Alcohol Dependence</i> , 2001, 64, 299-307.	3.2	8
306	Reinforcing and discriminative-stimulus effects of ephedrine isomers in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2001, 65, 45-53.	3.2	14
307	The subjective effects of MDMA and mCPP in moderate MDMA users. <i>Drug and Alcohol Dependence</i> , 2001, 65, 97-101.	3.2	140

#	ARTICLE	IF	CITATIONS
308	Lack of effect of intravenous hydrocortisone on mood in humans: a preliminary study. Behavioural Pharmacology, 2001, 12, 373-376.	1.7	11
309	Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers.. Experimental and Clinical Psychopharmacology, 2001, 9, 59-73.	1.8	80
310	Reinforcing and Subject-Rated Effects of Methylphenidate and d-Amphetamine in Non-Drug-Abusing Humans. Journal of Clinical Psychopharmacology, 2001, 21, 273-286.	1.4	100
311	What is a "low dose" of d -amphetamine for inducing behavioral effects in laboratory rats?. Psychopharmacology, 2001, 153, 155-169.	3.1	72
312	Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers. Psychopharmacology, 2001, 155, 362-371.	3.1	44
313	Repeated administration of the D 1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology, 2001, 155, 338-347.	3.1	81
314	Effects of repeated oral methamphetamine administration in humans. Psychopharmacology, 2001, 155, 397-404.	3.1	80
315	Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology, 2001, 157, 151-162.	3.1	221
316	Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology, 2001, 157, 163-167.	3.1	18
317	Mirthful laughter induced by subthalamic nucleus stimulation. Movement Disorders, 2001, 16, 867-875.	3.9	257
318	Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. Human Psychopharmacology, 2001, 16, 147-157.	1.5	16
319	Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 2001, 39, 32-41.	1.2	825
320	Pretreatment With Hydromorphone, a mu-Opioid Agonist, Does Not Alter the Acute Behavioral and Physiological Effects of Ethanol in Humans. Alcoholism: Clinical and Experimental Research, 2001, 25, 9-17.	2.4	9
321	Haloperidol Reduces Stimulant and Reinforcing Effects of Ethanol in Social Drinkers. Alcoholism: Clinical and Experimental Research, 2001, 25, 1448-1456.	2.4	35
322	Individual Differences in Responses to Ethanol and d-Amphetamine: A Within-Subject Study. Alcoholism: Clinical and Experimental Research, 2001, 25, 540-548.	2.4	48
323	Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology Biochemistry and Behavior, 2001, 68, 611-627.	2.9	307
324	Nicotine alters some of cocaine's subjective effects in the absence of physiological or pharmacokinetic changes. Pharmacology Biochemistry and Behavior, 2001, 69, 209-217.	2.9	41
325	Antiemetic efficacy of smoked marijuana. Pharmacology Biochemistry and Behavior, 2001, 69, 343-350.	2.9	45

#	ARTICLE	IF	CITATIONS
326	An fMRI Study of the Effect of Amphetamine on Brain Activity,. Neuropsychopharmacology, 2001, 25, 925-935.	5.4	36
327	Acute performance-impairing and subject-rated effects of triazolam and temazepam, alone and in combination with ethanol, in humans. Journal of Psychopharmacology, 2002, 16, 23-34.	4.0	12
328	Cardiovascular Responses Elicited by the "Binge" Administration of Methamphetamine. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 152-159.	2.5	69
329	Informed Decision-Making on Sympathomimetic Use in Sport and Health. Clinical Journal of Sport Medicine, 2002, 12, 209-224.	1.8	38
330	Acute behavioral and physiological effects of modafinil in drug abusers. Behavioural Pharmacology, 2002, 13, 105-115.	1.7	106
331	Establishment of a diazepam preference in human volunteers following a differential-conditioning history of placebo versus diazepam choice.. Experimental and Clinical Psychopharmacology, 2002, 10, 77-83.	1.8	38
332	Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biological Psychiatry, 2002, 51, 143-150.	1.3	15
333	A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients. Drug and Alcohol Dependence, 2002, 67, 177-183.	3.2	25
334	Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence, 2002, 67, 149-156.	3.2	191
335	Acute effects of oral cocaine on inhibitory control of behavior in humans. Drug and Alcohol Dependence, 2002, 67, 157-167.	3.2	118
336	Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug and Alcohol Dependence, 2002, 67, 311-322.	3.2	80
337	The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug and Alcohol Dependence, 2002, 68, 23-33.	3.2	127
338	Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology Biochemistry and Behavior, 2002, 71, 85-96.	2.9	11
339	Lack of effects of acute estradiol on mood in postmenopausal women. Pharmacology Biochemistry and Behavior, 2002, 71, 71-77.	2.9	12
340	Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacology Biochemistry and Behavior, 2002, 72, 559-568.	2.9	37
341	Differential subjective effects of d-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacology Biochemistry and Behavior, 2002, 73, 729-741.	2.9	218
342	Effects of oral contraceptives on acute cocaine response in female volunteers. Pharmacology Biochemistry and Behavior, 2002, 74, 173-180.	2.9	14
343	Acute Administration of d-Amphetamine Decreases Impulsivity in Healthy Volunteers. Neuropsychopharmacology, 2002, 27, 813-825.	5.4	382

#	ARTICLE	IF	CITATIONS
344	Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology, 2002, 160, 344-352.	3.1	52
345	High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology, 2002, 161, 202-212.	3.1	90
346	Biphasic Alcohol Response Differs in Heavy Versus Light Drinkers. Alcoholism: Clinical and Experimental Research, 2002, 26, 827-835.	2.4	203
347	Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology, 2003, 165, 146-156.	3.1	27
348	Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. Psychopharmacology, 2003, 165, 280-290.	3.1	57
349	Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology, 2003, 165, 359-369.	3.1	153
350	Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology, 2003, 167, 20-27.	3.1	35
351	Effects of stress on responses to methamphetamine in humans. Psychopharmacology, 2003, 170, 188-199.	3.1	39
352	Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology, 2003, 170, 242-254.	3.1	112
353	Behavioral and physiological effects of cocaine in humans following triazolam. Pharmacology Biochemistry and Behavior, 2003, 76, 383-392.	2.9	10
354	Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacology Biochemistry and Behavior, 2003, 75, 801-808.	2.9	32
355	Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Human Psychopharmacology, 2003, 18, 291-299.	1.5	60
356	Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Movement Disorders, 2003, 18, 524-530.	3.9	231
357	Comparative Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Nefopam in Healthy Volunteers*. Basic and Clinical Pharmacology and Toxicology, 2003, 92, 279-286.	0.0	40
358	Noradrenergic modulation of ephedrine-induced hypophagia. Synapse, 2003, 48, 18-24.	1.2	18
359	Discriminative-Stimulus Effects of Triazolam in Light and Moderate Drinkers. Alcoholism: Clinical and Experimental Research, 2003, 27, 638-646.	2.4	7
360	Mecamylamine Attenuates the Subjective Stimulant-Like Effects of Alcohol in Social Drinkers. Alcoholism: Clinical and Experimental Research, 2003, 27, 780-786.	2.4	91
361	Alcohol Choice and Amphetamine Effects in Light and Moderate Drinkers. Alcoholism: Clinical and Experimental Research, 2003, 27, 804-811.	2.4	12

#	ARTICLE	IF	CITATIONS
362	Effects of Acute Social Stress on Alcohol Consumption in Healthy Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 1270-1277.	2.4	101
363	Poison Centersâ€™ Experience With Methylphenidate Abuse in Pre-Teens and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 288-294.	0.5	76
364	Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 73-83.	2.5	285
365	Discriminative stimulus effects of (âˆ”)ephedrine in rats: analysis with catecholamine transporter and receptor ligands. <i>Drug and Alcohol Dependence</i> , 2003, 70, 255-264.	3.2	13
366	Principles of initial experimental drug abuse liability assessment in humans. <i>Drug and Alcohol Dependence</i> , 2003, 70, S41-S54.	3.2	174
367	Assessing abuse liability in clinical trials. <i>Drug and Alcohol Dependence</i> , 2003, 70, S87-S95.	3.2	77
368	Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. <i>Drug and Alcohol Dependence</i> , 2003, 72, 33-44.	3.2	125
369	Ephedrine-Type Alkaloid-Containing Dietary Supplements and Substance Dependence. <i>Psychosomatics</i> , 2003, 44, 508-511.	2.5	14
370	Differential Effects In Humans After Repeated Administrations Of Zolpidem And Triazolam. <i>American Journal of Drug and Alcohol Abuse</i> , 2003, 29, 281-299.	2.1	17
371	Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1757.	7.4	282
372	Risperidone Attenuates the Discriminative-Stimulus Effects of d-Amphetamine in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 195-204.	2.5	88
373	Effects of THC on Behavioral Measures of Impulsivity in Humans. <i>Neuropsychopharmacology</i> , 2003, 28, 1356-1365.	5.4	325
374	Association Between A2a Receptor Gene Polymorphisms and Caffeine-Induced Anxiety. <i>Neuropsychopharmacology</i> , 2003, 28, 1694-1702.	5.4	295
375	Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures. <i>Behavioral and Cognitive Neuroscience Reviews</i> , 2003, 2, 227-260.	3.9	37
376	Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure. <i>Behavioural Pharmacology</i> , 2003, 14, 97-109.	1.7	9
377	The prediction of individual differences in response to D-amphetamine in healthy adults. <i>Behavioural Pharmacology</i> , 2003, 14, 19-32.	1.7	20
378	Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 269-280.	1.4	25
379	D-cycloserine-naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure.. <i>Experimental and Clinical Psychopharmacology</i> , 2003, 11, 237-246.	1.8	7

#	ARTICLE	IF	CITATIONS
380	Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. American Journal of Clinical Nutrition, 2004, 80, 82-88.	4.7	85
381	Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology, 2004, 18, 534-543.	4.0	58
382	Amphetamine and Other Psychostimulants. , 2004, , 105-138.		0
383	Influence of Methylphenidate on Eating in Obese Men. Obesity, 2004, 12, 224-232.	4.0	86
384	Alcohol Effects During Acamprosate Treatment: A Dose-Response Study in Humans. Alcoholism: Clinical and Experimental Research, 2004, 28, 1074-1083.	2.4	37
385	Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacology Biochemistry and Behavior, 2004, 78, 57-64.	2.9	41
386	Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. European Journal of Pharmacology, 2004, 491, 157-168.	3.5	8
387	Reinforcing effect of pseudoephedrine isomers and the mechanism of action. European Journal of Pharmacology, 2004, 493, 117-125.	3.5	12
388	Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology, 2004, 173, 364-375.	3.1	120
389	Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology, 2004, 175, 391-8.	3.1	21
390	The effect of a herbal medicine(Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study. Human Psychopharmacology, 2004, 19, 235-241.	1.5	5
391	Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- β -methadol in opioid-naïve individuals*1. Clinical Pharmacology and Therapeutics, 2004, 76, 154-166.	4.7	24
392	Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers. Drug and Alcohol Dependence, 2004, 73, 133-140.	3.2	15
393	Pretreatment with transdermal nicotine enhances some of ethanol's acute effects in men. Drug and Alcohol Dependence, 2004, 75, 55-65.	3.2	82
394	Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug and Alcohol Dependence, 2004, 76, 81-91.	3.2	37
395	Alprazolam Attenuates the Behavioral Effects of d-Amphetamine in Humans. Journal of Clinical Psychopharmacology, 2004, 24, 410-420.	1.4	47
396	Effects of Naltrexone on the Subjective Response to Amphetamine in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2004, 24, 665-669.	1.4	75
397	Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. Journal of Clinical Psychopharmacology, 2004, 24, 479-487.	1.4	43

#	ARTICLE	IF	CITATIONS
398	Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology, 2004, 15, 91-102.	1.7	17
399	Reinforcing and Subjective Effects of Methylphenidate: Dose and Time in Bed.. Experimental and Clinical Psychopharmacology, 2004, 12, 180-189.	1.8	20
400	Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. Journal of Psychopharmacology, 2004, 18, 534-543.	4.0	68
401	Effects of haloperidol on reactions to smoking cues in humans. Behavioural Pharmacology, 2005, 16, 123-126.	1.7	23
402	The Use of Stimulants to Modify Performance During Sleep Loss: A Review by the Sleep Deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep, 2005, 28, 1163-1187.	1.1	146
403	Discriminative Stimulus and Self-Reported Effects of Methylphenidate, d-Amphetamine, and Triazolam in Methylphenidate-Trained Humans.. Experimental and Clinical Psychopharmacology, 2005, 13, 56-64.	1.8	30
404	Cocaine craving, euphoria, and self-administration: A preliminary study of the effect of catecholamine precursor depletion.. Behavioral Neuroscience, 2005, 119, 1619-1627.	1.2	106
405	Effects of d-amphetamine and smoking abstinence on cue-induced cigarette craving.. Experimental and Clinical Psychopharmacology, 2005, 13, 209-218.	1.8	7
406	Effects of repeated-dose isradipine on the abuse liability of cocaine.. Experimental and Clinical Psychopharmacology, 2005, 13, 319-326.	1.8	19
407	Depression and other psychological health problems among methamphetamine dependent patients in treatment: Implications for assessment and treatment outcome. Australian Psychologist, 2005, 40, 96-108.	1.6	24
408	Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 47-53.	1.9	42
409	Methadone doses of 100â€¢mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction, 2005, 100, 1496-1509.	3.3	99
410	Mecamylamine and Ethanol Preference in Healthy Volunteers. Alcoholism: Clinical and Experimental Research, 2005, 29, 58-65.	2.4	61
411	Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 2005, 82, 270-279.	2.9	11
412	Methylphenidate increases cigarette smoking. Psychopharmacology, 2005, 181, 781-789.	3.1	65
413	Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology, 2005, 183, 248-256.	3.1	109
414	Acute effects of alprazolam on risky decision making in humans. Psychopharmacology, 2005, 181, 364-373.	3.1	37
415	Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboonPapio anubis. Synapse, 2005, 56, 94-99.	1.2	47

#	ARTICLE	IF	CITATIONS
416	Human Cocaine-Seeking Behavior and its Control by Drug-Associated Stimuli in the Laboratory. <i>Neuropsychopharmacology</i> , 2005, 30, 433-443.	5.4	41
417	Effects of the Mixed Mu/Kappa Opioid Nalbuphine on Cocaine-Induced Changes in Subjective and Cardiovascular Responses in Men. <i>Neuropsychopharmacology</i> , 2005, 30, 618-632.	5.4	28
418	Dopamine Transporter Gene Associated with Diminished Subjective Response to Amphetamine. <i>Neuropsychopharmacology</i> , 2005, 30, 602-609.	5.4	139
419	Aripiprazole Attenuates the Discriminative-Stimulus and Subject-Rated Effects of D-Amphetamine in Humans. <i>Neuropsychopharmacology</i> , 2005, 30, 2103-2114.	5.4	71
420	Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events. <i>American Journal of Psychiatry</i> , 2005, 162, 189-191.	7.2	40
421	Functional Neuroanatomical Substrates of Altered Reward Processing in Major Depressive Disorder Revealed by a Dopaminergic Probe. <i>Archives of General Psychiatry</i> , 2005, 62, 1228.	12.3	321
422	A Pilot Study of Methylphenidate Preference Assessment in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 729-741.	1.3	18
423	Methods to assess potential reduced exposure products. <i>Nicotine and Tobacco Research</i> , 2005, 7, 827-844.	2.6	48
424	Attention-Deficit/Hyperactivity Disorder, Medication Treatment, and Substance Use Patterns Among Adolescents and Young Adults. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 799-809.	1.3	127
425	Effects of d-amphetamine in human models of information processing and inhibitory control. <i>Drug and Alcohol Dependence</i> , 2005, 77, 151-159.	3.2	46
426	Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. <i>Drug and Alcohol Dependence</i> , 2005, 78, 243-252.	3.2	28
427	Transdermal nicotine alters some of marijuana's effects in male and female volunteers. <i>Drug and Alcohol Dependence</i> , 2005, 79, 211-223.	3.2	93
428	Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. <i>Drug and Alcohol Dependence</i> , 2005, 80, 273-278.	3.2	52
429	Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. <i>Neuropharmacology</i> , 2005, 48, 1164-1171.	4.1	50
430	Psychiatric symptoms associated with ephedra use. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 879-884.	2.4	11
431	Toxicity and Drug Interactions Associated with Herbal Products: Ephedra and St. John's Wort. <i>Medical Clinics of North America</i> , 2005, 89, 1225-1257.	2.5	19
432	Bringing Ayahuasca to the Clinical Research Laboratory. <i>Journal of Psychoactive Drugs</i> , 2005, 37, 219-230.	1.7	45
433	Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 878-894.	2.0	142

#	ARTICLE	IF	CITATIONS
434	Discriminative-Stimulus Effects of Triazolam in Women and Men. American Journal of Drug and Alcohol Abuse, 2006, 32, 329-349.	2.1	5
435	Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. American Journal of Health-System Pharmacy, 2006, 63, 915-928.	1.0	50
436	Diazepam impairs behavioral inhibition but not delay discounting or risk taking in healthy adults.. Experimental and Clinical Psychopharmacology, 2006, 14, 190-198.	1.8	29
437	Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug and Alcohol Dependence, 2006, 81, 27-36.	3.2	55
438	Research design strategies to evaluate the impact of formulations on abuse liability. Drug and Alcohol Dependence, 2006, 83, S52-S62.	3.2	57
439	Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence, 2006, 85, 157-162.	3.2	168
440	Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.. Experimental and Clinical Psychopharmacology, 2006, 14, 136-147.	1.8	37
441	Intravenous cocaine discrimination in humans.. Experimental and Clinical Psychopharmacology, 2006, 14, 99-108.	1.8	17
442	Ramelteon. Archives of General Psychiatry, 2006, 63, 1149.	12.3	134
443	Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine.. Experimental and Clinical Psychopharmacology, 2006, 14, 413-421.	1.8	29
444	Evaluation of the Abuse Potential of Pagoclone, a Partial GABAA Agonist. Journal of Clinical Psychopharmacology, 2006, 26, 268-273.	1.4	9
445	Interactions on Mixing Diazepam With Methadone or Buprenorphine in Maintenance Patients. Journal of Clinical Psychopharmacology, 2006, 26, 274-283.	1.4	63
446	Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat. British Journal of Pharmacology, 2006, 149, 647-656.	5.4	14
447	Serotonin Transporter Genotype and Acute Subjective Response to Amphetamine. American Journal on Addictions, 2006, 15, 327-335.	1.4	28
448	Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatric Nephrology, 2006, 21, 92-95.	1.7	121
449	Moderate doses of ethanol fail to increase plasma levels of neurosteroid 3 α -hydroxy-5 α -pregnan-20-one-like immunoreactivity in healthy men and women. Psychopharmacology, 2006, 186, 442-450.	3.1	32
450	Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans. Psychopharmacology, 2006, 186, 544-552.	3.1	17
451	Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology, 2006, 186, 54-63.	3.1	74

#	ARTICLE	IF	CITATIONS
452	Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. <i>Psychopharmacology</i> , 2006, 185, 514-523.	3.1	175
453	Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. <i>Psychopharmacology</i> , 2006, 186, 93-98.	3.1	200
454	Stimulating effects of the antihistamine fexofenadine: testing the dopamine transporter hypothesis. <i>Psychopharmacology</i> , 2006, 187, 95-102.	3.1	16
455	Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. <i>Psychopharmacology</i> , 2006, 187, 268-283.	3.1	1,113
456	Individual differences in drug abuse vulnerability: d-Amphetamine and sensation-seeking status. <i>Psychopharmacology</i> , 2006, 189, 17-25.	3.1	105
457	The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. <i>Psychopharmacology</i> , 2006, 189, 565-573.	3.1	98
458	Dopamine-mediated actions of ephedrine in the rat substantia nigra. <i>Brain Research</i> , 2006, 1069, 96-103.	2.2	21
459	Cortisol effects of d-amphetamine relate to traits of fearlessness and aggression but not anxiety in healthy humans. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 123-131.	2.9	23
460	Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers. <i>Human Psychopharmacology</i> , 2006, 21, 549-559.	1.5	9
461	Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: A human pharmacological magnetic resonance imaging study at 1.5 and 4 T. <i>Magnetic Resonance in Medicine</i> , 2006, 55, 9-15.	3.0	19
462	An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 576-583.	1.7	35
463	Association between the Casein Kinase 1 Epsilon Gene Region and Subjective Response to D-Amphetamine. <i>Neuropsychopharmacology</i> , 2006, 31, 1056-1063.	5.4	56
464	Personality and the Subjective Effects of Acute Amphetamine in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2006, 31, 1064-1074.	5.4	69
465	Pressor Responses to Ephedrine Are Mediated by a Direct Mechanism in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 95-105.	2.5	27
467	Explaining the Escalation of Drug Use in Substance Dependence: Models and Appropriate Animal Laboratory Tests. <i>Pharmacology</i> , 2007, 80, 65-119.	2.2	127
468	Measurement of the Subjective Effects of Methylphenidate in 11- to 15-Year-Old Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 63-73.	1.3	18
469	Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmoticâ€Controlled Extendedâ€Release Methylphenidate Formulation in Humans. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1476-1488.	2.0	47
470	Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 749-759.	2.5	16

#	ARTICLE	IF	CITATIONS
471	Personality and gender differences in effects of d-amphetamine on risk taking.. Experimental and Clinical Psychopharmacology, 2007, 15, 599-609.	1.8	49
472	Behavioral and subjective effects of D-amphetamine and modafinil in healthy adults.. Experimental and Clinical Psychopharmacology, 2007, 15, 123-133.	1.8	59
473	Effects of oral cocaine on intravenous cocaine discrimination in humans.. Experimental and Clinical Psychopharmacology, 2007, 15, 219-227.	1.8	7
474	Do Formulation Differences Alter Abuse Liability of Methylphenidate?. Journal of Clinical Psychopharmacology, 2007, 27, 459-467.	1.4	65
475	The reinforcing, subject-rated, performance, and cardiovascular effects of d-amphetamine: Influence of sensation-seeking status. Addictive Behaviors, 2007, 32, 1177-1188.	3.0	78
476	Negative cocaine effect expectancies are associated with subjective response to cocaine challenge in recreational cocaine users. Addictive Behaviors, 2007, 32, 1262-1271.	3.0	16
477	Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug and Alcohol Dependence, 2007, 91, 187-194.	3.2	92
478	Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease. Clinical Therapeutics, 2007, 29, 1825-1849.	2.5	181
479	Norepinephrine Transporter Gene Variation Modulates Acute Response to d-Amphetamine. Biological Psychiatry, 2007, 61, 1296-1305.	1.3	39
480	Exogenous Acquired Metabolic Disorders of the Nervous System. , 2007, , 865-896.		4
481	Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food?. American Journal of Clinical Nutrition, 2007, 86, 308-315.	4.7	64
482	Agonist treatment for stimulant abuse and dependence. , 2007, , 145-167.		1
483	The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. British Journal of Clinical Pharmacology, 2007, 63, 680-688.	2.4	108
484	Monoamine Oxidaseâ€ Inhibition in the Treatment of Parkinson's Disease. Pharmacotherapy, 2007, 27, 174S-185S.	2.6	135
485	Does stress reactivity or response to amphetamine predict smoking progression in young adults? A preliminary study. Pharmacology Biochemistry and Behavior, 2007, 86, 312-319.	2.9	16
486	Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers. Pharmacology Biochemistry and Behavior, 2007, 86, 667-677.	2.9	9
487	Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans. Pharmacology Biochemistry and Behavior, 2007, 87, 20-29.	2.9	20
488	Evaluation of estradiol administration on the discriminative-stimulus and subject-rated effects of d-amphetamine in healthy pre-menopausal women. Pharmacology Biochemistry and Behavior, 2007, 87, 258-266.	2.9	16

#	ARTICLE	IF	CITATIONS
489	Similar discriminative-stimulus effects of d-amphetamine in women and men. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 87, 289-296.	2.9	21
490	Abuse Liability of Medications Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD). <i>American Journal on Addictions</i> , 2007, 16, 35-44.	1.4	52
491	Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. <i>Psychopharmacology</i> , 2008, 196, 105-116.	3.1	75
492	Evaluation of the mu and kappa opioid actions of buprenorphine in humans through differential naltrexone blockade. <i>Psychopharmacology</i> , 2008, 196, 143-155.	3.1	28
493	Modulation of human risky decision making by flunitrazepam. <i>Psychopharmacology</i> , 2008, 196, 177-188.	3.1	19
494	Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. <i>Psychopharmacology</i> , 2008, 196, 315-326.	3.1	48
495	Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. <i>Human Psychopharmacology</i> , 2008, 23, 693-705.	1.5	106
497	Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 607-614.	4.7	36
498	Subjective, Psychomotor, and Physiological Effects Profile of Hydrocodone/Acetaminophen and Oxycodone/Acetaminophen Combination Products: Table 1. <i>Pain Medicine</i> , 2008, 9, 433-443.	1.9	28
499	Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 573-579.	2.4	32
500	Disulfiram enhances subjective effects of dextroamphetamine in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 394-398.	2.9	16
501	Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: A retrospective analysis. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 787-796.	2.9	8
502	Approved and Investigational Uses of Modafinil. <i>Drugs</i> , 2008, 68, 1803-1839.	10.9	377
503	Enhanced mood and psychomotor performance by a caffeine-containing energy capsule in fatigued individuals. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 13-21.	1.8	64
504	Abuse liability assessment of atomoxetine in a drug-abusing population. <i>Drug and Alcohol Dependence</i> , 2008, 95, 140-146.	3.2	80
505	The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , 2008, 98, 191-202.	3.2	136
506	Pharmacologic mechanisms of crystal meth. <i>Cmaj</i> , 2008, 178, 1679-1682.	2.0	141
507	Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 729-41.	2.1	33

#	ARTICLE	IF	CITATIONS
508	Naltrexone Attenuates the Subjective Effects of Amphetamine in Patients with Amphetamine Dependence. <i>Neuropsychopharmacology</i> , 2008, 33, 1856-1863.	5.4	89
509	Development of Medications for Heroin and Cocaine Addiction and Regulatory Aspects of Abuse Liability Testing. , 2008, , 221-270.		2
510	Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: A pilot case-control study.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 429-434.	1.8	42
511	Bupropion improves attention but does not affect impulsive behavior in healthy young adults.. <i>Experimental and Clinical Psychopharmacology</i> , 2008, 16, 113-123.	1.8	74
512	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , 2008, 193, 65-72.	2.8	64
513	Effects of Low to Moderate Acute Doses of Pramipexole on Impulsivity and Cognition in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 45-51.	1.4	85
514	No Relation between Therapeutic Response to Methylphenidate and its Cardiovascular Side Effects in Children with Attention-Deficit/Hyperactivity Disorder. <i>Clinical Medicine Pediatrics</i> , 2008, 1, CMPed.S1010.	0.1	0
515	Nicotine Pretreatment Increases Dysphoric Effects of Alcohol in Luteal-Phase Female Volunteers. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 526-546.	2.6	5
516	Reflections on the past 40 Years of Behavioral Pharmacology Research on Problems of Drug Abuse. <i>Journal of Drug Issues</i> , 2009, 39, 133-151.	1.2	4
517	Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. <i>Journal of Psychopharmacology</i> , 2009, 23, 410-418.	4.0	86
518	Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. <i>Journal of Psychopharmacology</i> , 2009, 23, 419-427.	4.0	126
519	The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 94, 108-113.	2.9	34
520	Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: A randomized cross-over trial. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 94, 98-107.	2.9	24
521	Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function. <i>Human Psychopharmacology</i> , 2009, 24, 371-389.	1.5	12
522	Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). <i>Psychopharmacology</i> , 2009, 204, 73-83.	3.1	41
523	Further evidence of association between amphetamine response and SLC6A2 gene variants. <i>Psychopharmacology</i> , 2009, 206, 501-511.	3.1	41
524	Determining the subjective and physiological effects of BZP on human females. <i>Psychopharmacology</i> , 2009, 207, 439-446.	3.1	80
525	A review of the clinical pharmacology of methamphetamine. <i>Addiction</i> , 2009, 104, 1085-1099.	3.3	588

#	ARTICLE	IF	CITATIONS
526	Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. British Journal of Clinical Pharmacology, 2009, 67, 299-308.	2.4	23
527	Proof of concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addiction Biology, 2009, 14, 73-83.	2.6	98
528	Subjective Effects of <i>Salvia Divinorum</i> : LSD- or Marijuana-like?. Journal of Psychoactive Drugs, 2009, 41, 213-217.	1.7	30
529	Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug and Alcohol Dependence, 2009, 101, 107-114.	3.2	51
530	Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence, 2009, 105, S14-S25.	3.2	174
531	Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment. Drug and Alcohol Dependence, 2009, 105, 209-214.	3.2	22
532	Amphetamine-Induced Place Preference in Humans. Biological Psychiatry, 2009, 65, 900-904.	1.3	124
533	Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users. Clinical Drug Investigation, 2009, 29, 777-790.	2.2	57
534	Pharmacogenetic Treatments for Drug Addiction: Cocaine, Amphetamine and Methamphetamine. American Journal of Drug and Alcohol Abuse, 2009, 35, 161-177.	2.1	63
535	Discriminative Stimulus and Subject-Rated Effects of Methamphetamine, d-Amphetamine, Methylphenidate, and Triazolam in Methamphetamine-Trained Humans. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 1007-1018.	2.5	52
536	Methadone-Nicotine Interactions in Methadone Maintenance Treatment Patients. Journal of Clinical Psychopharmacology, 2009, 29, 231-238.	1.4	61
537	Performance and subjective effects of diazepam and d-amphetamine in high and low sensation seekers. Behavioural Pharmacology, 2009, 20, 505-517.	1.7	25
538	Major Depressive Disorder and Patient Satisfaction in Relation to Methadone Pharmacokinetics and Pharmacodynamics in Stabilized Methadone Maintenance Patients. Journal of Clinical Psychopharmacology, 2009, 29, 77-81.	1.4	26
539	GABAergic modulation of human social interaction in a prisoner's dilemma model by acute administration of alprazolam. Behavioural Pharmacology, 2009, 20, 657-661.	1.7	15
540	Repeated dosing with oral cocaine in humans: Assessment of direct effects, withdrawal, and pharmacokinetics.. Experimental and Clinical Psychopharmacology, 2009, 17, 205-216.	1.8	41
541	Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana.. Experimental and Clinical Psychopharmacology, 2009, 17, 217-225.	1.8	86
542	Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: An exploratory study with d-amphetamine in healthy participants.. Experimental and Clinical Psychopharmacology, 2009, 17, 374-383.	1.8	98
543	Reinforcing effects of d-amphetamine. Behavioural Pharmacology, 2010, 21, 745-753.	1.7	14

#	ARTICLE	IF	CITATIONS
544	Behavioral effects of γ -hydroxybutyrate in humans. Behavioural Pharmacology, 2010, 21, 332-342.	1.7	28
545	Differential effect of codeine on thermal nociceptive sensitivity in sleepy versus nonsleepy healthy subjects.. Experimental and Clinical Psychopharmacology, 2010, 18, 277-283.	1.8	24
546	Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech. Psychopharmacology, 2010, 208, 169-177.	3.1	28
547	Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology, 2010, 210, 521-531.	3.1	25
548	Determining the subjective effects of TFMPP in human males. Psychopharmacology, 2010, 211, 347-353.	3.1	69
549	Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology, 2010, 212, 193-203.	3.1	65
550	Polymorphisms in Dopamine Transporter (SLC6A3) are Associated with Stimulant Effects of d-Amphetamine: An Exploratory Pharmacogenetic Study Using Healthy Volunteers. Behavior Genetics, 2010, 40, 255-261.	2.1	24
551	A possible link between sensation-seeking status and positive subjective effects of oxycodone in healthy volunteers. Pharmacology Biochemistry and Behavior, 2010, 95, 113-120.	2.9	24
552	Human sex differences in <i>d</i> -amphetamine self-administration. Addiction, 2010, 105, 727-731.	3.3	35
553	Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users. Clinical Pharmacology and Therapeutics, 2010, 88, 69-78.	4.7	39
554	Methamphetamine Psychosis in Australia, Philippines, and Thailand. Addictive Disorders and Their Treatment, 2010, 9, 143-149.	0.5	10
555	Behavioral Effects of d-Amphetamine in Humans: Influence of Subclinical Levels of Inattention and Hyperactivity. American Journal of Drug and Alcohol Abuse, 2010, 36, 220-227.	2.1	3
556	Sustained Release d-Amphetamine Reduces Cocaine but not Δ^9 -THC Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers. Neuropsychopharmacology, 2010, 35, 2624-2637.	5.4	60
557	More Aroused, Less Fatigued: Fatty Acid Amide Hydrolase Gene Polymorphisms Influence Acute Response to Amphetamine. Neuropsychopharmacology, 2010, 35, 613-622.	5.4	29
558	Remission of Persistent Methamphetamine-Induced Psychosis After Electroconvulsive Therapy: Presentation of a Case and Review of the Literature. American Journal of Psychiatry, 2010, 167, 17-23.	7.2	61
559	The clinical toxicology of metamfetamine. Clinical Toxicology, 2010, 48, 675-694.	1.9	116
560	Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug and Alcohol Dependence, 2010, 106, 173-180.	3.2	55
561	Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug and Alcohol Dependence, 2010, 107, 69-75.	3.2	20

#	ARTICLE	IF	CITATIONS
562	Psychopharmacological effects of oxycodone in healthy volunteers: Roles of alcohol-drinking status and sex. <i>Drug and Alcohol Dependence</i> , 2010, 107, 209-214.	3.2	26
563	Oral ketamine as a positive control in human abuse potential studies. <i>Drug and Alcohol Dependence</i> , 2010, 114, 185-93.	3.2	18
564	Gender Differences in Subjective and Physiological Responses to Caffeine and the Role of Steroid Hormones. <i>Journal of Caffeine Research</i> , 2011, 1, 41-48.	0.9	85
566	The Evolution of Concepts. , 2011, , 7-21.		1
567	How ephedrine escaped regulation in the United States: A historical review of misuse and associated policy. <i>Health Policy</i> , 2011, 99, 1-9.	3.0	42
568	Oral methylphenidate establishes a conditioned place preference in rats. <i>Neuroscience Letters</i> , 2011, 487, 293-296.	2.1	20
569	Abuse potential of stimulant drugs used to treat ADHD. , 0, , 230-239.		0
570	Progesterone effects on the discriminative stimulus, subjective and performance effects of triazolam in healthy, premenopausal women. <i>Behavioural Pharmacology</i> , 2011, 22, 441-449.	1.7	1
571	Absence of Psychostimulant Effects of a Supratherapeutic Dose of Tianeptine. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 441-448.	1.4	15
572	Discriminative-Stimulus, Subject-Rated, and Physiological Effects of Methamphetamine in Humans Pretreated With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 470-480.	1.4	29
573	Psychopharmacological effects of oxycodone in volunteers with and without generalized anxiety disorder.. <i>Experimental and Clinical Psychopharmacology</i> , 2011, 19, 85-94.	1.8	6
574	Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance.. <i>Experimental and Clinical Psychopharmacology</i> , 2011, 19, 433-444.	1.8	52
575	The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. <i>Addiction</i> , 2011, 106, 1460-1473.	3.3	64
576	Amphetamine Self-Administration in Light and Moderate Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 443-453.	2.4	7
577	Healthy Subjects with a Family History of Alcoholism Show Increased Stimulative Subjective Effects of Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, no-no.	2.4	11
578	Subjective Response to Alcohol Challenge: A Quantitative Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 1759-1770.	2.4	205
579	OPRM1 gene variants modulate amphetamine-induced euphoria in humans. <i>Genes, Brain and Behavior</i> , 2011, 10, 199-209.	2.2	44
580	Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 97, 627-631.	2.9	42

#	ARTICLE	IF	CITATIONS
581	The safety of modafinil in combination with oral Δ^9 -tetrahydrocannabinol in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 98, 94-100.	2.9	17
582	Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 138-143.	2.9	14
583	Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. <i>Drug Testing and Analysis</i> , 2011, 3, 582-585.	2.6	62
584	Apnea-hypopnea indices and snoring in children diagnosed with ADHD: a matched case-control study. <i>Sleep and Breathing</i> , 2011, 15, 455-462.	1.7	16
585	Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. <i>Psychopharmacology</i> , 2011, 213, 61-68.	3.1	55
586	Determining the subjective and physiological effects of BZP combined with TFMPP in human males. <i>Psychopharmacology</i> , 2011, 214, 761-768.	3.1	29
587	Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women. <i>Psychopharmacology</i> , 2011, 215, 429-439.	3.1	10
588	Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. <i>Psychopharmacology</i> , 2011, 218, 471-481.	3.1	37
589	Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. <i>Psychopharmacology</i> , 2011, 218, 649-665.	3.1	638
590	Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. <i>BMC Neurology</i> , 2011, 11, 112.	1.8	30
591	Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. <i>Depression and Anxiety</i> , 2011, 28, 999-1007.	4.1	22
592	A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. <i>Human Psychopharmacology</i> , 2011, 26, 224-236.	1.5	68
593	MDMA (‘ecstasy’) abuse as an example of dopamine neuroplasticity. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 1203-1218.	6.1	33
594	The predictive validity of the rat self-administration model for abuse liability. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 912-938.	6.1	157
595	Genetic Factors Modulating the Response to Stimulant Drugs in Humans. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 12, 537-577.	1.7	30
596	Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1111-1125.	1.8	14
597	Comparison of the Behavioral and Cardiovascular Effects of Intranasal and Oral <i>d</i> -Amphetamine in Healthy Human Subjects. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 888-898.	2.0	26
598	Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. <i>Journal of Psychopharmacology</i> , 2011, 25, 1469-1479.	4.0	22

#	ARTICLE	IF	CITATIONS
599	Effects of 24 Hours of Tobacco Withdrawal and Subsequent Tobacco Smoking Among Low and High Sensation Seekers. <i>Nicotine and Tobacco Research</i> , 2011, 13, 943-954.	2.6	11
600	Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 717-726.	1.4	109
601	Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid. <i>Journal of Psychopharmacology</i> , 2011, 25, 763-773.	4.0	11
602	Subjective Effects, Misuse, and Adverse Effects of Osmotic-Release Methylphenidate Treatment in Adolescent Substance Abusers with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 455-463.	1.3	39
603	Stimulant and Sedative Effects of Alcohol. <i>Current Topics in Behavioral Neurosciences</i> , 2011, , 489-509.	1.7	87
604	Acute Effects of Marijuana Smoking on Negative and Positive Affect. <i>Journal of Cognitive Psychotherapy</i> , 2011, 25, 31-46.	0.4	51
606	Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 492-502.	1.4	13
607	Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers. <i>Current Pharmaceutical Design</i> , 2012, 18, 4966-4979.	1.9	225
608	The behavioral pharmacology of anorexigenic drugs in nonhuman primates. <i>Behavioural Pharmacology</i> , 2012, 23, 461-477.	1.7	5
609	Intranasal oxycodone self-administration in non-dependent opioid abusers.. <i>Experimental and Clinical Psychopharmacology</i> , 2012, 20, 310-317.	1.8	3
610	Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. <i>Journal of Psychopharmacology</i> , 2012, 26, 1289-1298.	4.0	42
611	Is Cognitive Functioning Impaired in Methamphetamine Users? A Critical Review. <i>Neuropsychopharmacology</i> , 2012, 37, 586-608.	5.4	195
612	Subjective and psychomotor effects of carisoprodol in combination with oxycodone in healthy volunteers. <i>Drug and Alcohol Dependence</i> , 2012, 120, 229-232.	3.2	11
613	Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers. <i>Drug and Alcohol Dependence</i> , 2012, 124, 274-282.	3.2	19
614	Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. <i>Pain</i> , 2012, 153, 2315-2324.	4.2	49
615	Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking. <i>Psychopharmacology</i> , 2012, 223, 489-499.	3.1	125
617	MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. <i>Psychopharmacology</i> , 2012, 222, 293-302.	3.1	128
618	Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect. <i>Journal of Neural Transmission</i> , 2012, 119, 701-707.	2.8	23

#	ARTICLE	IF	CITATIONS
619	Comparison of intranasal methamphetamine and <i>d</i> -amphetamine self-administration by humans. <i>Addiction</i> , 2012, 107, 783-791.	3.3	69
620	Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase. <i>European Journal of Pharmacology</i> , 2012, 683, 226-230.	3.5	4
621	Varenicline Potentiates Alcohol-Induced Negative Subjective Responses and Offsets Impaired Eye Movements. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 906-914.	2.4	42
622	Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 560-565.	2.9	38
623	Pharmacology of ayahuasca administered in two repeated doses. <i>Psychopharmacology</i> , 2012, 219, 1039-1053.	3.1	108
624	Effects of amphetamine on reactivity to emotional stimuli. <i>Psychopharmacology</i> , 2012, 220, 143-153.	3.1	46
625	Effects of the NK ₁ antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. <i>Addiction Biology</i> , 2013, 18, 332-343.	2.6	35
626	Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. <i>BMC Research Notes</i> , 2013, 6, 220.	1.4	33
627	In the company of others: social factors alter acute alcohol effects. <i>Psychopharmacology</i> , 2013, 230, 215-226.	3.1	62
628	The drug effects questionnaire: psychometric support across three drug types. <i>Psychopharmacology</i> , 2013, 227, 177-192.	3.1	165
629	Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. <i>Psychopharmacology</i> , 2013, 226, 381-392.	3.1	101
630	Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 779-787.	1.9	17
631	Efficacy of psychostimulant drugs for amphetamine abuse or dependence. <i>The Cochrane Library</i> , 2013, , CD009695.	2.8	52
632	Individual predictors of the subjective effects of intravenous cocaine. <i>Psychiatry Research</i> , 2013, 208, 245-251.	3.3	6
633	Personality and the acute subjective effects of <i>d</i> -amphetamine in humans. <i>Journal of Psychopharmacology</i> , 2013, 27, 256-264.	4.0	34
634	A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to <i>d</i> -amphetamine, methylphenidate and modafinil. <i>Neuropharmacology</i> , 2013, 73, 348-358.	4.1	49
635	Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. <i>European Journal of Pharmacology</i> , 2013, 715, 424-435.	3.5	5
636	Pharmacological characterization of designer cathinones <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2013, 168, 458-470.	5.4	576

#	ARTICLE	IF	CITATIONS
638	Candidate Gene Studies of a Promising Intermediate Phenotype: Failure to Replicate. <i>Neuropsychopharmacology</i> , 2013, 38, 802-816.	5.4	69
639	Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans. <i>Psychopharmacology</i> , 2013, 226, 515-529.	3.1	23
640	Abuse liability and reinforcing efficacy of oral tramadol in humans. <i>Drug and Alcohol Dependence</i> , 2013, 129, 116-124.	3.2	110
641	Methylphenidate. <i>CNS Drugs</i> , 2013, 27, 1-14.	5.9	40
642	Conditioned Preference to a Methamphetamine-Associated Contextual Cue in Humans. <i>Neuropsychopharmacology</i> , 2013, 38, 921-929.	5.4	34
643	Abuse potential of propofol used for sedation in gastric endoscopy and its correlation with subject characteristics. <i>Korean Journal of Anesthesiology</i> , 2013, 65, 403.	2.5	11
644	Comparative abuse liability of GHB and ethanol in humans.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 112-123.	1.8	21
645	Relationship between drug discrimination and ratings of subjective effects. <i>Behavioural Pharmacology</i> , 2013, 24, 523-532.	1.7	5
646	Relationship between oral D-amphetamine self-administration and ratings of subjective effects. <i>Behavioural Pharmacology</i> , 2013, 24, 533-542.	1.7	12
647	Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. <i>Journal of Addiction Research & Therapy</i> , 2014, 05, 176.	0.2	11
648	Hydration and Urinary Pseudoephedrine Levels After a Simulated Team Game. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2014, 24, 325-332.	2.1	3
649	Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 371-381.	2.1	117
650	Comparison of Subjective Effects of Extended-Release Versus Immediate-Release Oxycodone/Acetaminophen Tablets in Healthy Nondependent Recreational Users of Prescription Opioids: A Randomized Trial. <i>Postgraduate Medicine</i> , 2014, 126, 20-32.	2.0	17
651	Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. <i>Addiction</i> , 2014, 109, 1489-1500.	3.3	59
652	The Pathology of Methamphetamine Use in the Human Brain. , 2014, , 203-297.		3
653	Amphetamine Increases Errors During Episodic Memory Retrieval. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 85-92.	1.4	30
654	Anxiety-Inducing Dietary Supplements: A Review of Herbs and Other Supplements with Anxiogenic Properties. <i>Pharmacology & Pharmacy</i> , 2014, 05, 966-981.	0.7	2
655	Dopamine D3 receptors as a therapeutic target for methamphetamine dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2014, 40, 1-9.	2.1	16

#	ARTICLE	IF	CITATIONS
656	Genetic variation associated with euphorigenic effects of <i>d</i>-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5968-5973.	7.1	18
657	Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. CNS Drugs, 2014, 28, 361-372.	5.9	15
658	Effects of oxycodone on brain responses to emotional images. Psychopharmacology, 2014, 231, 4403-4415.	3.1	17
659	Dopamine reuptake transporter (DAT) â€œinverse agonismâ€• A novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacology, 2014, 87, 19-40.	4.1	47
660	Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology, 2014, 87, 81-90.	4.1	25
661	Acute Effects of 3,4-Methylenedioxymethamphetamine and Methylphenidate on Circulating Steroid Levels in Healthy Subjects. Neuroendocrinology, 2014, 100, 17-25.	2.5	49
662	Unmasking of familial long QT syndrome type 2 with crystal methamphetamine exposure. Heart Rhythm, 2014, 11, 1836-1838.	0.7	4
664	Subjective Responses to Caffeine Are Influenced by Caffeine Dose, Sex, and Pubertal Stage. Journal of Caffeine Research, 2015, 5, 167-175.	0.9	17
665	Marijuanaâ€™s acute effects on cognitive bias for affective and marijuana cues.. Experimental and Clinical Psychopharmacology, 2015, 23, 339-350.	1.8	23
666	Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation. Human Psychopharmacology, 2015, 30, 213-224.	1.5	38
667	Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers. British Journal of Clinical Pharmacology, 2015, 80, 480-492.	2.4	14
668	Effects of Acute Methamphetamine on Emotional Memory Formation in Humans: Encoding vs Consolidation. PLoS ONE, 2015, 10, e0117062.	2.5	11
669	A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial. PLoS ONE, 2015, 10, e0140501.	2.5	52
670	Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart. European Neuropsychopharmacology, 2015, 25, 1637-1649.	0.7	24
671	Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids. Postgraduate Medicine, 2015, 127, 13-21.	2.0	3
672	Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 2015, 29, 289-299.	4.0	768
673	Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. International Journal of Neuropsychopharmacology, 2015, 18, pyv065.	2.1	46
674	Clinical Evaluation of Abuse Potential for New Pharmaceuticals. , 2015, , 215-243.		0

#	ARTICLE	IF	CITATIONS
675	Acquisition of Responses to a Methamphetamine-Associated Cue in Healthy Humans: Self-Report, Behavioral, and Psychophysiological Measures. <i>Neuropsychopharmacology</i> , 2015, 40, 1734-1741.	5.4	32
676	Dopamine Regulates Approach-Avoidance in Human Sensation-Seeking. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv041.	2.1	19
677	Multivariate analysis of subjective responses to d-amphetamine in healthy volunteers finds novel genetic pathway associations. <i>Psychopharmacology</i> , 2015, 232, 2781-2794.	3.1	7
678	Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective $\alpha 7$ Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies. <i>Clinical Therapeutics</i> , 2015, 37, 311-324.	2.5	45
679	An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. <i>Journal of Substance Abuse Treatment</i> , 2015, 48, 96-103.	2.8	28
680	Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. <i>Biological Psychiatry</i> , 2015, 78, 544-553.	1.3	340
681	Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers. <i>Psychopharmacology</i> , 2015, 232, 63-73.	3.1	15
682	Acquisition of Conditioning between Methamphetamine and Cues in Healthy Humans. <i>PLoS ONE</i> , 2016, 11, e0161541.	2.5	5
683	Stimulants for the Control of Hedonic Appetite. <i>Frontiers in Pharmacology</i> , 2016, 7, 105.	3.5	22
684	Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals. <i>Journal of Addiction Medicine</i> , 2016, 10, 156-165.	2.6	12
685	Safety and Tolerability of Biphasic Immediateâ€Release/Extendedâ€Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials. <i>Pain Practice</i> , 2016, 16, 856-868.	1.9	4
686	Delayed emergence of methamphetamineâ€™s enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence. <i>Drug and Alcohol Dependence</i> , 2016, 159, 181-189.	3.2	6
687	Acute effects of cannabis on breath-holding duration.. <i>Experimental and Clinical Psychopharmacology</i> , 2016, 24, 305-312.	1.8	11
688	Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial. <i>Epilepsy and Behavior</i> , 2016, 61, 63-71.	1.7	9
689	Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. <i>Human Psychopharmacology</i> , 2016, 31, 356-372.	1.5	34
690	Effects of d-amphetamine upon psychosocial stress responses. <i>Journal of Psychopharmacology</i> , 2016, 30, 608-615.	4.0	10
691	Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. <i>Drug and Alcohol Dependence</i> , 2016, 159, 26-34.	3.2	16
692	Extinction of Conditioned Responses to Methamphetamine-Associated Stimuli in Healthy Humans. <i>Psychopharmacology</i> , 2016, 233, 2489-2502.	3.1	6

#	ARTICLE	IF	CITATIONS
693	Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 1161-1175.	0.7	123
694	Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology. <i>Journal of Psychopharmacology</i> , 2016, 30, 330-343.	4.0	9
695	Emotional traits predict individual differences in amphetamine-induced positive mood in healthy volunteers. <i>Psychopharmacology</i> , 2016, 233, 89-97.	3.1	57
696	Safety pharmacology of acute MDMA administration in healthy subjects. <i>Journal of Psychopharmacology</i> , 2017, 31, 576-588.	4.0	107
697	Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 712-720.	2.1	30
698	Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 474-488.	2.5	105
699	Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. <i>Drug and Alcohol Dependence</i> , 2017, 177, 136-144.	3.2	84
700	Associations Between Behavioral and Neural Correlates of Inhibitory Control and Amphetamine Reward Sensitivity. <i>Neuropsychopharmacology</i> , 2017, 42, 1905-1913.	5.4	23
701	Atomoxetine in abstinent cocaine users: Sex differences. <i>Data in Brief</i> , 2017, 14, 566-572.	1.0	3
702	Randomized, Double-Blind, Placebo- and Active Comparatorâ€“Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 675-683.	1.4	6
703	Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 159, 55-61.	2.9	9
704	Sweet taste liking is associated with subjective response to amphetamine in women but not men. <i>Psychopharmacology</i> , 2017, 234, 3185-3194.	3.1	14
705	Lobeline Effects on Cognitive Performance in Adult ADHD. <i>Journal of Attention Disorders</i> , 2018, 22, 1361-1366.	2.6	17
706	Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans. <i>Neuropsychopharmacology</i> , 2018, 43, 1498-1509.	5.4	33
707	Rewarding effects of physical activity predict sensitivity to the acute subjective effects of d-amphetamine in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2018, 32, 302-308.	4.0	2
708	Adsorption properties of graphene towards the ephedrine â€“ A frequently used molecule in sport. <i>Computational and Theoretical Chemistry</i> , 2018, 1124, 39-50.	2.5	12
709	Neural activation to monetary reward is associated with amphetamine reward sensitivity. <i>Neuropsychopharmacology</i> , 2018, 43, 1738-1744.	5.4	19
710	Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. <i>Psychopharmacology</i> , 2018, 235, 467-479.	3.1	91

#	ARTICLE	IF	CITATIONS
711	Studies with psychedelic drugs in human volunteers. <i>Neuropharmacology</i> , 2018, 142, 116-134.	4.1	23
712	Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. <i>Epilepsy and Behavior</i> , 2018, 78, 194-201.	1.7	5
713	Triangulating abuse liability assessment for flavoured cigar products using physiological, behavioural economic and subjective assessments: a within-subjects clinical laboratory protocol. <i>BMJ Open</i> , 2018, 8, e023850.	1.9	4
714	Improving the Clinical Pharmacologic Assessment of Abuse Potential. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 113-118.	1.4	2
715	Improving the Clinical Pharmacologic Assessment of Abuse Potential. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 11-18.	1.4	1
716	A Biological/Genetic Perspective: The Addicted Brain. <i>Issues in Children's and Families' Lives</i> , 2018, , 23-65.	0.2	0
717	Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 926-931.	2.1	63
718	Δ ⁹ -Tetrahydrocannabinol at Retrieval Drives False Recollection of Neutral and Emotional Memories. <i>Biological Psychiatry</i> , 2018, 84, 743-750.	1.3	23
719	Continuous Monitoring Using a Wearable Device Detects Activity-Induced Heart Rate Changes After Administration of Amphetamine. <i>Clinical and Translational Science</i> , 2019, 12, 677-686.	3.1	29
720	Influence of electronic cigarette liquid flavors and nicotine concentration on subjective measures of abuse liability in young adult cigarette smokers. <i>Drug and Alcohol Dependence</i> , 2019, 203, 27-34.	3.2	22
721	Developing a phone-based measure of impairment after acute oral Δ ⁹ -tetrahydrocannabinol. <i>Journal of Psychopharmacology</i> , 2019, 33, 1160-1169.	4.0	10
722	Subjective responses to amphetamine in young adults with previous mood elevation experiences. <i>Psychopharmacology</i> , 2019, 236, 3363-3370.	3.1	5
723	The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 113.	3.0	18
724	Gender differences in the behavioral and subjective effects of methamphetamine in healthy humans. <i>Psychopharmacology</i> , 2019, 236, 2413-2423.	3.1	46
725	Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. <i>Biological Psychiatry</i> , 2019, 86, 792-800.	1.3	104
726	A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis. <i>Substance Use and Misuse</i> , 2019, 54, 549-559.	1.4	48
727	Nano-biosensors and Nano-aptasensors for Stimulant Detection. <i>Environmental Chemistry for A Sustainable World</i> , 2019, , 169-193.	0.5	1
728	Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 186, 212-225.	2.5	14

#	ARTICLE	IF	CITATIONS
729	Sympathomimetic amine compounds and hepatotoxicity: Not all are alike”Key distinctions noted in a short review. Toxicology Reports, 2019, 6, 26-33.	3.3	12
730	Validation of a behavioral economic purchase task for assessing drug abuse liability. Addiction Biology, 2019, 24, 303-314.	2.6	26
731	Δ ⁹ -Tetrahydrocannabinol During Encoding Impairs Perceptual Details yet Spares Context Effects on Episodic Memory. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 110-118.	1.5	6
732	Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep, 2020, 43, .	1.1	179
733	Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 461-467.	1.5	33
734	Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology, 2020, 45, 462-471.	5.4	141
736	Anticipation of monetary reward in amygdala, insula, caudate are predictors of pleasure sensitivity to d-Amphetamine administration. Drug and Alcohol Dependence, 2020, 206, 107725.	3.2	13
737	Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels. Advances in Therapy, 2020, 37, 3967-3984.	2.9	0
738	Δ ⁹ -Tetrahydrocannabinol (THC) impairs visual working memory performance: a randomized crossover trial. Neuropsychopharmacology, 2020, 45, 1807-1816.	5.4	19
739	Retrospectively assessed subjective effects of initial opioid use differ between opioid misusers with opioid use disorder (OUD) and those who never progressed to OUD: Data from a pilot and a replication sample. Journal of Neuroscience Research, 2022, 100, 353-361.	2.9	6
740	The Ibogaine Experience: A Qualitative Study on the Acute Subjective Effects of Ibogaine. Anthropology of Consciousness, 2020, 31, 91-119.	1.1	14
741	High Recreational Gamblers Show Increased Stimulatory Effects of an Acute Laboratory Gambling Challenge. Journal of Gambling Studies, 2021, 37, 299-318.	1.6	2
742	Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults. Neuroscience and Biobehavioral Reviews, 2021, 120, 123-158.	6.1	23
743	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. International Journal of Neuropsychopharmacology, 2021, 24, 171-180.	2.1	6
744	Application of Cognitive Test Outcomes for Clinical Drug Development. , 2021, , 183-197.		0
745	PHARMACODYNAMIC AND PHARMACOKINETIC INTERACTIONS OF HERBS WITH PRESCRIBED DRUGS: A REVIEW. Plant Archives, 2021, 21, 185-198.	0.2	3
746	What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomedical Journal, 2021, 6, e128.	1.0	15
747	Comparative study between active and passive exposure of methamphetamine vapor in mice. Forensic Toxicology, 2021, 39, 394-404.	2.4	1

#	ARTICLE	IF	CITATIONS
748	Effect of Δ^9 -Tetrahydrocannabinol on frontostriatal resting state functional connectivity and subjective euphoric response in healthy young adults. Drug and Alcohol Dependence, 2021, 221, 108565.	3.2	9
749	A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers. Scientific Reports, 2021, 11, 9876.	3.3	5
750	Subjective responses predict d-amphetamine choice in healthy volunteers. Pharmacology Biochemistry and Behavior, 2021, 204, 173158.	2.9	3
751	Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open, 2021, 11, e044696.	1.9	11
752	First-in-class human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management. British Journal of Clinical Pharmacology, 2021, , .	2.4	4
753	Alcohol conditioned contexts enhance positive subjective alcohol effects and consumption. Behavioural Processes, 2021, 187, 104340.	1.1	6
754	Adolescents' Understanding of Opioid-Induced Euphoria Measures and Proposed Measurement Revisions. Journal of Psychoactive Drugs, 2021, , 1-11.	1.7	0
755	Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 372-385.	2.5	22
756	Analytical techniques for the detection of amphetamine-type substances in different matrices: A comprehensive review. TrAC - Trends in Analytical Chemistry, 2021, 145, 116447.	11.4	23
757	Stimulant and Sedative Effects of Alcohol. Current Topics in Behavioral Neurosciences, 2011, 13, 489-509.	1.7	65
758	Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence. , 2010, , 129-157.		2
759	Addiction Research Center Inventory (ARCI): Measurement of Euphoria and Other Drug Effects. , 1987, , 489-524.		52
760	A Drug Preference Procedure for use with Human Volunteers. , 1987, , 559-572.		11
761	What is the Influence of Subthalamic Nucleus Stimulation on the Limbic Loop?. , 2001, , 333-340.		5
762	Central Stimulants. , 1981, , 1-65.		10
763	Physiological and Behavioral Effects of Intravenous Cocaine in Man. Advances in Behavioral Biology, 1977, , 647-664.	0.2	7
764	Structure-Activity Relationships of Several Amphetamine Drugs in Man. Advances in Behavioral Biology, 1977, , 705-715.	0.2	6
765	Drugs as Discriminable Events in Humans. Advances in Behavioral Biology, 1977, , 187-206.	0.2	15

#	ARTICLE	IF	CITATIONS
766	The Catecholamines: Possible Role in Affect, Mood, and Emotional Behavior in Man and Animals. , 1975, , 73-117.		12
767	Central Nervous System Stimulants: Historical Aspects and Clinical Effects. , 1978, , 99-165.		20
768	Behavioral Pharmacology of Cocaine. , 1998, , 187-200.		5
769	Behavioral Approaches to Individual Differences in Substance Abuse. , 1985, , 125-175.		13
770	Neuropsychological Sequelae of Substance Abuse by Youths. Critical Issues in Neuropsychology, 1989, , 311-331.	0.4	3
771	Ma Huang and the Ephedra Alkaloids. , 2007, , 1-26.		2
772	The Evolution of Concepts of Opioid Receptors. , 1988, , 3-22.		6
773	Empirische Untersuchung veränderter Bewusstseinszustände. , 2016, , 1-25.		9
774	General Problems of Drug Abuse and Drug Dependence. , 1977, , 3-40.		10
775	Amphetamine Dependence; Clinical Features. , 1977, , 277-304.		3
776	Relationship Between the Discriminative Stimulus Properties and Subjective Effects of Drugs. , 1988, 4, 161-175.		131
777	Assessment of the Abuse Potential of Amphetamines and LSD-Like Hallucinogens in Man and its Relationship to Basic Animal Assessment Programs. Bayer-Symposium, 1973, , 146-159.	0.1	12
778	Methylphenidate in Hyperactive and Enuretic Children. , 1984, , 183-195.		14
779	Predicting the Abuse Liability of Drugs with Animal Drug Self-Administration Procedures: Psychomotor Stimulants and Hallucinogens. Advances in Behavioral Pharmacology, 1979, , 163-208.	0.6	90
781	The potential for abuse of stimulants in chronically sleep-restricted populations. , 0, , 122-135.		1
782	Variations in affect following amphetamine and placebo: Markers of stimulant drug preference.. Experimental and Clinical Psychopharmacology, 2003, 11, 91-101.	1.8	26
783	A follow-up study of the acute behavioral effects of benzodiazepine-receptor ligands in humans: Comparison of quazepam and triazolam.. Experimental and Clinical Psychopharmacology, 1999, 7, 257-265.	1.8	5
784	Information on nutritional supplement labels: time for legislation?. South African Journal of Clinical Nutrition, 2012, 25, 22-26.	0.7	8

#	ARTICLE	IF	CITATIONS
785	Individual Differences in Responses to Ethanol and d-Amphetamine: A Within-Subject Study. Alcoholism: Clinical and Experimental Research, 2001, 25, 540-548.	2.4	2
786	Biphasic Alcohol Response Differs in Heavy Versus Light Drinkers. Alcoholism: Clinical and Experimental Research, 2002, 26, 827-835.	2.4	8
787	Comparative Abuse Liability of Sertraline, Alprazolam, and Dextroamphetamine in Humans. Journal of Clinical Psychopharmacology, 1995, 15, 117-124.	1.4	38
788	Acute Tolerance to Subjective but not Cardiovascular Effects of d-Amphetamine in Normal, Healthy Men. Journal of Clinical Psychopharmacology, 1996, 16, 72-76.	1.4	53
789	Zolpidem, Triazolam, and Temazepam. Journal of Clinical Psychopharmacology, 1996, 16, 146-157.	1.4	90
790	Benzodiazepine-Receptor Ligands in Humans. Journal of Clinical Psychopharmacology, 1998, 18, 154-166.	1.4	26
791	Sibutramine. Journal of Clinical Psychopharmacology, 1998, 18, 231-236.	1.4	49
792	Laboratory Measures of Methylphenidate Effects in Cocaine-Dependent Patients Receiving Treatment. Journal of Clinical Psychopharmacology, 2000, 20, 61-68.	1.4	34
793	Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability. Journal of Clinical Psychopharmacology, 2000, 20, 435-444.	1.4	46
794	Human Pharmacology of 3,4-Methylenedioxymeth-amphetamine ("Ecstasy"): Psychomotor Performance and Subjective Effects. Journal of Clinical Psychopharmacology, 2000, 20, 455-466.	1.4	185
795	Comparative Abuse Liability of Intravenously Administered Remifentanyl and Fentanyl. Journal of Clinical Psychopharmacology, 2000, 20, 597-606.	1.4	28
796	Biphasic Inotropic Effects of Methamphetamine and Methylphenidate on Ferret Papillary Muscles. Journal of Cardiovascular Pharmacology, 1997, 30, 744-749.	1.9	5
798	Cortical-Limbic-Striatal Dysfunction in Depression: Converging Findings in Basal Ganglia Diseases and Primary Affective Disorders. , 0, , 321-338.		3
799	The effects of vitamin B on the brain damages caused by methamphetamine in mice. Iranian Journal of Basic Medical Sciences, 2018, 21, 434-438.	1.0	12
800	Stimulant Use in Sports. American Journal on Addictions, 1998, 7, 243-255.	1.4	10
801	Banned, but Not Forgotten. Primary Care Companion To the Journal of Clinical Psychiatry, 2004, 6, 136-137.	0.6	5
802	Cardiovascular and Subjective Effects of the Novel Adenosine A2A Receptor Antagonist SYN115 in Cocaine Dependent Individuals. Journal of Addiction Research & Therapy, 2012, 01, .	0.2	9
803	Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Medical Weekly, 2011, 141, w13267.	1.6	32

#	ARTICLE	IF	CITATIONS
804	Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects. Psychophysiology, 2022, 59, e13955.	2.4	5
805	Phendimetrazine-Induced Persistent Psychosis: A Case Report. Psychiatric Annals, 2021, 51, 497-500.	0.1	0
806	Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology, 2022, 239, 1735-1747.	3.1	33
808	Designing and interpreting the results of first-time-to-man studies. Dialogues in Clinical Neuroscience, 2000, 2, 203-212.	3.7	3
809	Pretreatment With Hydromorphone, a μ -Opioid Agonist, Does Not Alter the Acute Behavioral and Physiological Effects of Ethanol in Humans. Alcoholism: Clinical and Experimental Research, 2001, 25, 9-17.	2.4	0
810	Stimulants. Lung Biology in Health and Disease, 2004, , 387-446.	0.1	0
811	Neurochemistry of Drug Abuse. , 2006, , 429-558.		0
812	AmphÃ©tamine et autres psychostimulants. , 2007, , 129-170.		0
813	Neurochemical and Neurobehavioral Consequences of Methamphetamine Abuse. , 2007, , 53-79.		1
814	A Biological/Genetic Perspective: The Addicted Brain. , 2009, , 15-43.		0
815	Natural Stimulants. , 2008, , 209-260.		0
816	Abuse Liability Evaluation. , 2013, , 1-6.		0
817	Measurement of subjective effects. Japanese Journal of Clinical Pharmacology and Therapeutics, 1974, 5, 136-143.	0.1	0
818	An International Convention on the Control of Psychotropic Substances. Handbook of Experimental Pharmacology, 1982, , 409-424.	1.8	0
819	The Pharmacology of Amphetamines. , 1991, , 113-123.		0
821	The Effects of Cocaine in Buprenorphine-Maintained Outpatient Volunteers:Results from Clinical Experience and Laboratory Challenges. American Journal on Addictions, 1994, 3, 129-143.	1.4	6
822	Stimulant Drugs. Handbook of Experimental Pharmacology, 1995, , 421-442.	1.8	1
824	Behavioral Pharmacology of Opiates. , 1998, , 343-362.		1

#	ARTICLE	IF	CITATIONS
825	Natural Stimulants. , 2015, , 225-272.		0
826	La terapia farmacologica dell'alcolismo: i farmaci anti-alcol non ancora autorizzati dagli organismi regolatori ma utilizzati nella pratica clinica o in fase di sperimentazione. I farmaci che modulano il sistema del glutammato: il topiramato e il gabapent. Mission, 2017, , .	0.1	0
827	Empirische Untersuchung verÄnderter BewusstseinszustÄnde. , 2018, , 153-171.		2
828	Bupropion: an empirical pharmacological approach to drug development. , 1983, , 195-224.		0
829	Identification of Optimal Measures of Human Abuse Potential. Journal of Clinical Psychopharmacology, 2020, 40, 568-578.	1.4	1
830	Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts: Protocol for a Longitudinal Study Using a New Internet-Based Methodology. JMIR Research Protocols, 2021, 10, e24433.	1.0	3
831	Establishment of a diazepam preference in human volunteers following a differential-conditioning history of placebo versus diazepam choice.. Experimental and Clinical Psychopharmacology, 2002, 10, 77-83.	1.8	13
832	Ephedra and its application to sport performance: another concern for the athletic trainer?. Journal of Athletic Training, 2001, 36, 420-4.	1.8	22
833	Neurochemical and psychoanalytical approaches to mania. Journal of the Royal Society of Medicine, 1977, 70, 20-5.	0.1	1
834	Repeated low doses of LSD in healthy adults: A placeboâ€œcontrolled, doseâ€œresponse study. Addiction Biology, 2022, 27, e13143.	2.6	28
835	Adolescents are more sensitive than adults to acute behavioral and cognitive effects of THC. Neuropsychopharmacology, 2022, 47, 1331-1338.	5.4	15
836	Delta-9-tetrahydrocannabinol reduces willingness to exert effort in women. Psychopharmacology, 2022, 239, 1487-1497.	3.1	3
837	Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). PLoS ONE, 2022, 17, e0264927.	2.5	7
838	Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.. Experimental and Clinical Psychopharmacology, 1998, 6, 367-374.	1.8	59
839	Sleepiness and the reinforcing and subjective effects of methylphenidate.. Experimental and Clinical Psychopharmacology, 1999, 7, 145-150.	1.8	27
840	The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. Psychopharmacology, 2022, 239, 1783-1796.	3.1	7
841	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 118, 110570.	4.8	6
842	Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate. Current Medical Research and Opinion, 2022, 38, 1237-1250.	1.9	5

#	ARTICLE	IF	CITATIONS
843	Effects of Oral Delta-9-Tetrahydrocannabinol in Women During the Follicular Phase of the Menstrual Cycle. Cannabis and Cannabinoid Research, 2023, 8, 1117-1125.	2.9	1
844	Subjective and Cardiovascular Responses to an Acute Laboratory Gambling Task in Men and Women. Frontiers in Psychiatry, 0, 13, .	2.6	0
845	The altered state of consciousness induced by Δ^9 -THC. Consciousness and Cognition, 2022, 102, 103357.	1.5	3
847	USE OF d-AMPHETAMINE AND RELATED CENTRAL NERVOUS SYSTEM STIMULANTS IN CHILDREN. Pediatrics, 1973, 51, 302-305.	2.1	7
848	Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. Journal of Clinical Psychopharmacology, 2022, 42, 365-373.	1.4	11
849	Can the type of subjective response to first opioid exposure predict the risk of opioid use disorder? A scoping review. Brain Research Bulletin, 2022, 188, 67-76.	3.0	2
850	Facilitated extinction of conditioned fear responses by delta 9-tetrahydrocannabinol in humans: a pilot study. Human Psychopharmacology, 2022, 37, .	1.5	1
851	Methamphetamine, amphetamine, and aggression in humans: A systematic review of drug administration studies. Neuroscience and Biobehavioral Reviews, 2022, 141, 104805.	6.1	6
852	Seeing in Visionary and Mystical Experience: A Perceptual and Cognitive-Semantic Account. Cognitive Semantics, 2022, 8, 323-344.	0.3	0
853	Doping control in horses in the Czech Republic in 2010-2019. Acta Veterinaria Brno, 2023, 92, 39-46.	0.5	0
854	Selective and reversible chemical sensor for methamphetamine detection using AlEgen and cucurbit[7]uril. Chinese Journal of Analytical Chemistry, 2023, 51, 100275.	1.7	1
855	Anger, agency, risk and action: a neurobehavioral model with proof-of-concept in healthy young adults. Frontiers in Psychology, 0, 14, .	2.1	2
856	Details in Conducting Human Laboratory Alcohol Administration and Self-Administration Experiments to Assess Subjective Response and Craving for Alcohol. Neuromethods, 2023, , 159-188.	0.3	0
857	Factors associated with euphoria in a large subset of cases using propofol sedation during gastrointestinal endoscopy. Frontiers in Psychiatry, 0, 14, .	2.6	0
858	Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants. Clinical Pharmacology in Drug Development, 0, , .	1.6	0
860	Methamphetamine alters nucleus accumbens neural activation to monetary loss in healthy young adults. Psychopharmacology, 2023, 240, 1891-1900.	3.1	2
861	Expectancy for Adderall influences subjective mood and drug effects regardless of concurrent caffeine ingestion: A randomized controlled trial. Psychopharmacology, 0, , .	3.1	0
862	A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ^9 -Tetrahydrocannabivarin in Healthy Participants. Cannabis and Cannabinoid Research, 2023, 8, S71-S82.	2.9	0

#	ARTICLE	IF	CITATIONS
863	Ventilatory effects of fentanyl, heroin, and <i>d</i>-methamphetamine, alone and in mixtures, in male rats breathing normal air . Journal of Pharmacology and Experimental Therapeutics, 0, , JPET-AR-2023-001653.	2.5	1
864	Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology, 0, , .	5.4	2
865	Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Journal of Psychopharmacology, 2024, 38, 19-32.	4.0	1
866	Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology, Drug Discovery, and Beyond. Journal of Attention Disorders, 0, , .	2.6	0
867	Brain Glutamate Dynamics Predict Positive Agency in Healthy Women: Insights from Combined Application of Pharmacological Challenge, Comprehensive Affective Assessment, and Magnetic Resonance Spectroscopy. ACS Chemical Neuroscience, 2024, 15, 491-502.	3.5	0